

27 September - 1 October | Amsterdam, Netherlands

PROGRAMME



G104/105 Session 08:00 - 19:15

OSCE examination : Thoracic ultrasound training programme Part 3 - OSCE examination - by invitation only

Aims: BY INVITATION ONLY - This session is the final part of the ERS Thoracic ultrasound training programme, for more information on the programme and how to register please visit: https://www.ersnet.org/education-and-professional-development/ers-certified-training-programmes/thoracic-ultrasound-certified-training-programme/

Chairs: Christian Borbjerg Laursen (Odense M, Denmark), Najib M. Rahman (Oxford, United Kingdom), Rahul Bhatnagar (Bristol, United Kingdom), Nick Maskell (Bristol (Avon), United Kingdom), Jouke T. Annema (Amsterdam, Netherlands), Laurence M.M.J. Crombag (Amsterdam, Netherlands), Lars Konge (Copenhagen, Denmark, Denmark), Chair to be confirmed

Cromong (1	thistertain, retilentials), but konge (Copenhagen, Bennark, Bennark), chan to be committed
08:15	TUS Part 3 - OSCE: Round 1 Laurence M.M.J. Crombag (Amsterdam, Netherlands), Speaker to be confirmed
09:20	TUS Part 3 - OSCE: Round 2 Laurence M.M.J. Crombag (Amsterdam, Netherlands), Nick Maskell (Bristol (Avon), United Kingdom), Speaker to be confirmed
10:25	TUS Part 3 - OSCE: Round 3 Eihab Bedawi (Sheffield, United Kingdom), Radhika Banka (Mumbai (Maharashtra), India), Speaker to be confirmed
11:30	TUS Part 3 - OSCE: Round 4 Eihab Bedawi (Sheffield, United Kingdom), Radhika Banka (Mumbai (Maharashtra), India), Speaker to be confirmed
12:35	TUS Part 3 - OSCE: Round 5 Laurence M.M.J. Crombag (Amsterdam, Netherlands), Eihab Bedawi (Sheffield, United Kingdom), Nick Maskell (Bristol (Avon), United Kingdom), Speaker to be confirmed
13:40	TUS Part 3 - OSCE: Round 6 Laurence M.M.J. Crombag (Amsterdam, Netherlands), Jesper Rømhild Davidsen (Odense C, Denmark), Nick Maskell (Bristol (Avon), United Kingdom), Speaker to be confirmed
14:45	TUS Part 3 - OSCE: Round 7 Beenish Iqbal (Oxford, United Kingdom), Speaker to be confirmed
15:50	TUS Part 3 - OSCE: Round 8 Beenish Iqbal (Oxford, United Kingdom), Jesper Rømhild Davidsen (Odense C, Denmark), Speaker to be confirmed
16:55	TUS Part 3 - OSCE: Round 9 Jesper Rømhild Davidsen (Odense C, Denmark), Speaker to be confirmed
18:00	TUS Part 3 - OSCE: Round 10 Søren Helbo Skaarup (Aarhus C, Denmark), Beenish Iqbal (Oxford, United Kingdom), Jesper Rømhild Davidsen (Odense C, Denmark), Speaker to be confirmed

Elicium 1 Session 09:00 - 17:40

1

Postgraduate course: PG1 Thoracic ultrasound - €

Additional registration is required for this session.

Chairs: Rahul Bhatnagar (Bristol, United Kingdom), Beenish Iqbal (Oxford, United Kingdom), Najib M. Rahman (Oxford, United Kingdom), Radhika Banka (Mumbai (Maharashtra), India)

Welcome and introduction Speaker to be confirmed

O9:10 Focused cardiac ultrasound Casper Falster (Odense, Denmark)

09:30	Case: Focused cardiac ultrasound Casper Falster (Odense, Denmark)
09:40	Limited compression ultrasonography of the deep veins for deep vein thrombosis assessment Speaker to be confirmed
10:00	Case: Limited compression ultrasonography Speaker to be confirmed
10:10	Ultrasound assessment of the diaphragm Søren Helbo Skaarup (Aarhus C, Denmark)
10:30	Case: Ultrasound assessment of the diaphragm Søren Helbo Skaarup (Aarhus C, Denmark)
10:40	Discussion and Q&A Speaker to be confirmed
10:50	Coffee break Speaker to be confirmed
11:20	Use of thoracic ultrasound in an intensive care unit Silvia Mongodi (Pavia, Italy)
11:40	Case: Use of thoracic ultrasound in an intensive care unit Silvia Mongodi (Pavia, Italy)
11:50	Use of thoracic ultrasound in an interstitial lung disease clinic Jesper Rømhild Davidsen (Odense C, Denmark)
12:10	Case: Use of thoracic ultrasound in an interstitial lung disease clinic Jesper Rømhild Davidsen (Odense C, Denmark)
12:20	Use of evidence-based training principles in thoracic ultrasound in a department Speaker to be confirmed
12:40	Case: Use of evidence-based training principles in thoracic ultrasound in a department Speaker to be confirmed
12:50	Discussion and Q&A Speaker to be confirmed
13:00	Lunch break Speaker to be confirmed
14:00	Advanced thoracic ultrasound for assessment of patients with pleural disease Eihab Bedawi (Sheffield, United Kingdom)
14:20	Case: Advanced thoracic ultrasound for assessment of patients with pleural disease Eihab Bedawi (Sheffield, United Kingdom)
14:30	Advanced thoracic ultrasound for assessment of patients with chest opacity Christian Borbjerg Laursen (Odense M, Denmark)
14:50	Case: Advanced thoracic ultrasound for assessment of patients with chest opacity Christian Borbjerg Laursen (Odense M, Denmark)
15:00	Discussion and Q&A Speaker to be confirmed
15:10	Ultrasound-guided biopsy of the pleura Dinesh Addala (Oxford, United Kingdom)
15:30	Case: Ultrasound-guided biopsy of the pleura Dinesh Addala (Oxford, United Kingdom)
15:40	Ultrasound-guided biopsy of lymph nodes Anand Sundaralingam (Oxford, United Kingdom)

2

16:00	Case: Ultrasound-guided biopsy of lymph nodes Anand Sundaralingam (Oxford, United Kingdom)		
16:10	Break		
16:30	Ultrasound-guided biopsy of the lung Speaker to be confirmed		
16:50	Case: Ultrasound-guided biopsy of the lung Speaker to be confirmed		
17:00	Thoracic ultrasound for advanced procedure guidance Wui Mei Chew (Singapore, Singapore)		
17:20	Case: Thoracic ultrasound for advanced procedure guidance Wui Mei Chew (Singapore, Singapore)		
17:30	Discussion and Q&A Speaker to be confirmed		
2 4	Carrie II	00.00	17.00

<u>09:00 - 17:00</u> Session

NEXT: Networking Excellence Training Programme (NEXT)

Manuscript writing and publishing - Q&A discussion

Aims: By invitation only - The ERS NEXT programme provides a comprehensive training programme for ERS early career abstract presenters

16:15

Chairs: Th	omas Gille (Bobigny, France)
09:00	Welcome and overview of the day Thomas Gille (Bobigny, France)
09:15	Ice-breaker Thomas Gille (Bobigny, France)
09:30	Presentation skills lecture Dorina Esendagli (Ankara, Turkey)
10:00	Presentation skills breakout (oral presentations: beginners) Mathieu Marillier (Echirolles, France), Heleen Demeyer (Leuven, Belgium)
10:00	Presentation skills breakout (oral presentations: some experience) Marjolein A. Heuvelmans (Amsterdam, Netherlands), Matteo SICILIANO (ROMA, Italy)
10:00	Presentation skills breakout (oral presentations: experienced) Laura Fabbri (London, United Kingdom), Speaker to be confirmed
10:00	Presentation skills breakout (oral presentations: posters) Athénaïs Boucly (Paris, France), Christoph Fisser (Regensburg, Germany)
11:30	Coffee break
12:00	Complimentary skills to achieve success - round table discussions Augusta Beech (Manchester, United Kingdom)
13:00	Mentoring lunch (with ERS Leadership)
14:15	Moderating lecture Chiara Premuda (Palermo, Italy)
14:30	Moderating role-play session Christoph Fisser (Regensburg, Germany), Susanne Vijverberg (Amsterdam, Netherlands), Amanda Dandanell Juul (Odense S, Denmark)
15:15	Coffee break
15:45	Keynote: Manuscript writing and publishing Heleen Demeyer (Leuven, Belgium), Matteo SICILIANO (ROMA, Italy), Speaker to be confirmed

Heleen Demeyer (Leuven, Belgium), Matteo SICILIANO (ROMA, Italy), Speaker to be confirmed

3

16:45 Feedback and key take-home messages Thomas Gille (Bobigny, France)

E102	Session	09:00 - 17:15
Academ	y: Academy of adult respiratory medicine	
09:00	Introduction to workshops Sophia E. Schiza (Heraklion, Greece), Stylianos Loukides (Athens, Greece), Gabor Kovacs (Graz,	Austria)
09:15	Sleep-related disorders Dries Testelmans (Leuven, Belgium), Elisa Perger (Milano, Italy), Marieke L. Duiverman (Gronin Netherlands)	igen,
10:15	Coffee break	
10:45	Respiratory infections Letizia Traversi (Cittiglio, Italy)	
11:45	Pulmonary circulation Gabor Kovacs (Graz, Austria), Mona Lichtblau (Zürich, Switzerland)	
12:45	Lunch break	
13:45	Pulmonary function testing Frans H.C. De Jongh (Enschede, Netherlands), Monika Franczuk (Warsaw, Poland)	
14:45	Lung imaging Ádám Domonkos Tárnoki (Budapest, Hungary), Anna Kerpel-Fronius (Budapest, Hungary)	
15:45	Coffee break	
16:15	Thoracic oncology Maria Joana Pereira Catarata (Porto, Portugal), Wouter H. van Geffen (Leeuwarden, Netherlands)	

5D Session 09:30 - 13:00

Postgraduate course: PG4 Interpretation of adult and paediatric pulmonary function tests - € Additional registration is required for this session.

Aims: To understand the basic principles of spirometry and the importance of pattern recognition in different lung pathology for adults and paediatrics; to highlight the complexities in interpreting paediatric lung function and how to address this; to illustrate the different techniques in assessing airway resistance and bronchial hyperreactivity; to understand the basic principles of oscillometry and it's contribution to better understand lung problems in both adults and paediatrics; to provide a step by step guide on how to interpret arterial blood gas.

Disease(s): Airway diseases Interstitial lung diseases Paediatric respiratory diseases

Method(s): General respiratory patient care Physiology Pulmonary function testing

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Technical Assistant, Nurse, Paediatrician, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist

Chairs: Rachel Ong-Salvador (Amsterdam, Netherlands), Chair to be confirmed

09:30	Effective performance of spirometry for adult and paediatric patients Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom)
09:50	Discussion and Q&A Speaker to be confirmed
10:00	Case discussion: Effective performance of spirometry for adult and paediatric patients Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom)
10:15	Bronchoprovocation tests: effects on airway physiology testing Zuzana Diamant MD (Groningen, Netherlands)
10:35	Discussion and Q&A Speaker to be confirmed

4

10:45	Discussion: Bronchoprovocation tests Zuzana Diamant MD (Groningen, Netherlands)
11:00	Break
11:30	Understanding oscillometry: from theory to practice Robab Breyer-Kohansal (Wien, Austria)
11:50	Discussion and Q&A Speaker to be confirmed
12:00	Case discussion: Understanding oscillometry Robab Breyer-Kohansal (Wien, Austria)
12:15	Systematic approach to ABG interpretation Joost Gerard van den Aardweg (Amsterdam (NH), Netherlands)
12:35	Discussion and Q&A Speaker to be confirmed
12:45	Case discussion: Systematic approach to ABG interpretation Joost Gerard van den Aardweg (Amsterdam (NH), Netherlands)

5C Session 09:30 - 13:00

Postgraduate course: PG3 Diffuse interstitial lung diseases of known cause: diagnosis and management - €

Additional registration is required for this session.

Aims: 1) The attendees will learn a) how to interpret the HRCT finings to increase the suspicion or the diagnostic confidence of CTD-ILD/HP b) which are the main pitfalls in the interpretation of the HRCT. They will also learn when a lung biopsy sample is necessary to increase the diagnostic confidence of these disorders and which method is more likely to help in this regard. 2) The time of treatment initiation is of vital importance in these disorders. This topic will be thoroughly discussed. The choice of right immunosuppressive agent and the time of initiation of the antifibrotic treatment (i.e. before, concomitantly, after the initiation of immunomodulation will be discussed according to the current evidence in the literature. 3) In the final session, the management of the acute exacerbation of these disorders and the eligibility and time for ICU admission will be discussed. Moreover, right timing and eligibility of lung transplantation referral for the fibrotic forms which do not respond to treatment will also be discussed. This final session is an interactive one with involvement of the participants through multiple choice questions and round table discussion.

Disease(s): Interstitial lung diseases Respiratory critical care

Method(s): Endoscopy and interventional pulmonology Imaging Transplantation

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Radiologist, Thoracic surgeon

Chairs: Katerina Antoniou (Heraklion, Greece), Antoine Froidure (Bruxelles, Belgium)

09:30	Introduction Speaker to be confirmed
09:35	The patient's journey (pre-recorded)
09:40	HRCT and new imaging modalities in the evaluation of CTD-ILDs and HP Helmut Prosch (Wien, Austria)
10:00	Discussion and Q&A Speaker to be confirmed
10:10	Surgical lung biopsy vs cryobiopsy in CTD-ILDs and HP: when and which procedure is preferable Lauren Troy (Camperdown (NSW), Australia)
10:30	Discussion and Q&A Speaker to be confirmed
10:40	Connective Tissue Disease-ILD: immunomodulation or antifibrotics or both Catharina C. Moor (Rotterdam, Netherlands)
11:00	Discussion and Q&A Speaker to be confirmed

5

11:10	Break
11:30	Hypersensitivity Pneumonitis: immunomodulation or antifibrotics or both GEORGE MARGARITOPOULOS (THESSALONIKI, Greece)
11:50	Discussion and Q&A Speaker to be confirmed
12:00	Acute deterioration of DILDs of known cause: which patient should be admitted to ICU Elisabeth Bendstrup (Aarhus N, Denmark)
12:15	Acute deterioration of DILDs of known cause: which patient should be listed for lung transplantation Federica Meloni (Pavia (PV), Italy)
12:30	Round table discussion: Acute deterioration of DILDs of known cause Speaker to be confirmed

5B Session 09:30 - 13:00

Postgraduate course: PG2 Masterclass in asthma - € Additional registration is required for this session.

Aims: This PG aims to update fellow physicians on the latest findings on asthma pathophysiology and treatment advantages.

Method(s): Cell and molecular biology Epidemiology Physiology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Physician in Pulmonary Training

Chairs: Florence Schleich (Liège, Belgium), Gert-Jan Braunstahl (Rotterdam, Netherlands)

09:30	Asthma immunopathology and its clinical presentation Anneke ten Brinke (Leeuwarden, Netherlands)
09:50	Discussion and Q&A Speaker to be confirmed
10:00	Assessing patients with asthma is an art based on facts and knowledge of the diseases and our patients Matteo Bonini (Rome, Italy)
10:20	Discussion and Q&A Speaker to be confirmed
10:30	Asthma pharmacotherapy starts at the right step, with the right inhalations and inhalers, and moves accordingly Omar S. Usmani (London, United Kingdom)
10:50	Discussion and Q&A Speaker to be confirmed
11:00	Break
11:30	Assessing severe asthma and choosing the right biologic therapy Arnaud Bourdin (Montpellier Cedex 5, France)
11:50	Discussion and Q&A Speaker to be confirmed
12:00	Group assignment Speaker to be confirmed

Amtrium Session 09:30 - 13:00

Postgraduate course: PG6 Advanced skills in non-invasive ventilatory support - € Additional registration is required for this session.

Aims: To discuss the best practices in non-invasive respiratory support therapies for patients with acute and chronic respiratory failure; to review new developments in non-invasive respiratory support therapies (from high-flow nasal oxygen therapy to non-invasive ventilation).

6

Disease(s): Respiratory critical care Sleep and breathing disorders

Method(s): General respiratory patient care Pulmonary rehabilitation Respiratory intensive care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Medical Student, Respiratory critical care physician, Physician in Pulmonary Training, Respiratory physiotherapist

Chairs: João Carlos Winck (Vila Nova de Gaia, Portugal), Claudia Crimi (Catania (CT), Italy)

09:30	Non-invasive respiratory support for acute hypoxemic respiratory failure Laveena Munshi (Toronto, Canada)
09:50	Discussion and Q&A Speaker to be confirmed
10:00	Non-invasive respiratory support for acute hypercapnic respiratory failure Maria Laura Vega (Bologna, Italy)
10:20	Discussion and Q&A Speaker to be confirmed
10:30	Strategies for enhancing non-invasive respiratory support in NMD Tiina Andersen (Bergen, Norway)
10:50	Discussion and Q&A Speaker to be confirmed
11:00	Break
11:30	Ventilator integrated polygraphy to titrate HMV: the new kid on the block? Jesus Gonzalez (Montlignon, France)
11:50	Discussion and Q&A Speaker to be confirmed
12:00	Group assignment Speaker to be confirmed

3B Session 09:30 - 13:00

Postgraduate course: PG5 Managing pulmonary embolism: addressing controversies and exploring new strategies - €

Additional registration is required for this session.

Aims: This course is designed to provide a comprehensive, evidence-based approach to the management of PE across the spectrum of risk stratification. By equipping healthcare professionals with the latest knowledge and practical skills, it aims to improve clinical outcomes, streamline care delivery, and promote the adoption of best practices in PE management. The course aims to address the most controversial and relevant topics in the management of patients with pulmonary embolism (PE) through small working groups, with the goal of fostering interaction between instructors and participants.

Disease(s): Pulmonary vascular diseases Respiratory critical care

Method(s): General respiratory patient care Imaging Respiratory intensive care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Respiratory critical care physician, Physician in Pulmonary Training, Respiratory therapist

Chairs: Luis Jara-Palomares (Sevilla, Spain), Marion Delcroix (Leuven, Belgium)

1 1 4 4 1 DE 1 1 4 4 6 4

09:30	David Jiménez Castro (Madrid, Spain)
09:45	Discussion and Q&A Speaker to be confirmed
09:50	Guidelines in PE and latest clinical trials in PE Luis Jara-Palomares (Sevilla, Spain)
10:05	Discussion and Q&A Speaker to be confirmed

7

10:10	Process and challenges associated with starting a PERT program (mock PERT Call) Parth Rali (Philadelphia, United States)
10:25	Discussion and Q&A Speaker to be confirmed
10:30	Break
11:00	Case-based discussion breakouts Speaker to be confirmed
11:00	Group 1: Sound waves of clarity: the transthoracic echocardiography views of significance Olivier Sanchez (Paris, France)
11:00	Group 2: Case of intermediate risk PE
11:00	Group 3: Case with intermediate risk PE with clot in transit David Jiménez Castro (Madrid, Spain)
11:00	Group 4: Selecting an interventional device: one side doesn't fit all Parth Rali (Philadelphia, United States)
11:00	Group 5: Beyond the norm: exploring unique profiles of high-risk PE, including role of mechanic circulatory system Luis Jara-Palomares (Sevilla, Spain)
11:00	Group 6: Post PE dyspnoea
11:00	Group 7: Post PE follow-up and surveillance Speaker to be confirmed
11:00	Group 8: Q&A on how to operationalize PERT at your institution Belinda Rivera-Lebron (Pittsburgh, United States)

Elicium 2 Session 09:30 - 11:00

Forum: Primary and integrated respiratory care: part 1
Achieving universal coverage for lung health. Key actions in the Primary Care framework

Aims: To foster discussions and propose optimal strategies for enhancing universal health concerning respiratory diseases within Primary Care interventions. This includes identifying early life exposures that may pose a risk for lung disease and exploring preventive measures, taking into account various examples of community-based interventions and initiatives. Furthermore, it aims to describe and investigate the implementation of pulmonary rehabilitation and palliative care by primary care health providers across diverse cultural and economic contexts

Disease(s): Airway diseases Respiratory infections

Method(s): Epidemiology General respiratory patient care Palliative care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Respiratory physiotherapist, Respiratory therapist, Journalist

Chairs: Cláudia Sofia De Almeida Vicente Ferreira (Coimbra, Portugal), Luke Daines (Edinburgh (Edinburgh), United Kingdom)

09:30	Intervening early in the life course to reduce the risk of lung disease Speaker to be confirmed
09:45	A community-based approach to managing COPD in a Low and Middle Income Country Tara Ballav Adhikari (Kathamndu, Nepal)
10:00	How can a health system be developed to deliver rehabilitation for chronic respiratory diseases in low resource settings G M Monsur Habib (Khulna, Bangladesh)
10:15	What are the challenges and benefits of providing integrated respiratory and palliative care in urban and rural settings? Natasha Smallwood (Melbourne (VIC), Australia)
10:30	Discussion and Q&A Speaker to be confirmed

8

G106/107 Session 10:40 - 13:00

Skills workshop: SW1 SW1 - Pulmonary rehabilitation: extending practice to improve health outcomes

Additional registration is required for this session.

Aims: To describe diagnostic methods and interventions that enable phenotyping individuals based on the clinical problems experienced and tailoring the content of pulmonary rehabilitation programmes to deliver a personalised approach; to describe methods of assessing physical activity level and promoting physical activity; to assess patients who may benefit from neuromuscular electrical stimulation, and to be able to apply and progress the treatment; and to describe and evaluate the incorporation of mindfulness-based interventions into pulmonary rehabilitation and their outcomes.

Disease(s): Airway diseases Interstitial lung diseases Pulmonary vascular diseases

Method(s): General respiratory patient care Physiology Pulmonary rehabilitation

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist

Chairs: Andre Nyberg (Umeå, Sweden)

10:40	Introduction Speaker to be confirmed
10:50	Physical activity assessment and intervention Fabio De Oliveira Pitta (Londrina, Brazil)
10:50	Neuromuscular electrical stimulation - in who and how? Roy Meys (Heerlen, Netherlands)
10:50	How to improve balance and reduce fall in people undergoing pulmonary rehabilitation Speaker to be confirmed
10:50	Implementing mindfulness interventions into pulmonary rehabilitation Alice Malpass (Bristol, United Kingdom)

5A Session 11:15 - 12:45

Language session: French programme 2025

A joint ERS/SPLF session

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Paediatrician

Chairs: Claire Andrejak (Amiens, France), François-Xavier Blanc (Nantes Cedex 1, France)

11:15 Bronchial cancer and pollution Alexis Cortot (Lille, France)

11:30 Recent therapeutic trials in pulmonary fibrosis Vincent Cottin (Lyon, France)

11:45 Therapeutic news in PAH: impact on the management algorithm Athénaïs Boucly (Paris, France)

12:00 Short course treatment of tuberculosis in children Speaker to be confirmed

12:15 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session 11:15 - 12:45

Forum: Primary and integrated respiratory care: part 2 Global threats to respiratory health. Real challenges to improve

Aims: To address real problems of clinical management in respiratory health in primary health care - such as vaccine hesitancy, the impact of pollution and climate change, and inappropriate inhaler medication use and which changes are needed and can bring great benefits to the patient and to the community.

Explore and learn how to manage patient information regarding vaccination, antibiotic use and the use of chronic versus rescue medication, making doctor-patient communication more efficient and with greater adherence to best practice. Identify strategies to improve respiratory health outcomes and promote effective public health

9

Disease(s): Airway diseases Respiratory infections

Method(s): Epidemiology General respiratory patient care Public health

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Respiratory physiotherapist, Journalist

Chairs: Luke Daines (Edinburgh (Edinburgh), United Kingdom), Chair to be confirmed

11:15	Strategies for Family Physicians to Mitigate Air Pollution and Manage Chronic Respiratory Conditions Speaker to be confirmed
11:30	Vaccination hesitancy - major issues in daily practice Speaker to be confirmed
11:45	Antibiotics resistance and climate change Speaker to be confirmed
12:00	Patients' beliefs and impact on health and environment. María Mar Martínez Vázquez (Bilbao (Bizkaia), Spain)
12:15	Discussion and Q&A Speaker to be confirmed

5D Session 14:00 - 17:30

Postgraduate course: PG9 Cardiopulmonary exercise testing in clinical practice: applying the basics to understand respiratory issues - € Additional registration is required for this session.

Aims: 1. To provide attendees with an introduction to cardiopulmonary exercise testing (CPET), including the basics of interpretation, in the context of clinical respiratory practice.

2. To discuss the different patterns of abnormalities detected on CPET, to help clinicians utilise this test in respiratory clinics and help with management of patients.

3. To provide attendees with a step by step approach to interpretation of CPET, with worked case examples.

4. To describe the physiological abnormalities that can be detected on CPET and how these correlate with symptoms, in patients with respiratory illness.

Disease(s): Airway diseases

Method(s): Physiology Pulmonary function testing Pulmonary rehabilitation

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Thoracic surgeon, Respiratory therapist

Chairs: James H. Hull (London, United Kingdom), Afroditi Boutou (Thessaloniki, Greece)

14:00	What is cardiopulmonary exercise testing (CPET) and what role does it play in a respiratory service? Michele Schaeffer (Vancouver, Canada)
14:30	Discussion and Q&A Speaker to be confirmed
14:40	How do you interpret a cardiopulmonary exercise test? Hayley Lewthwaite (Merewether, Australia)
15:10	Discussion and Q&A Speaker to be confirmed
15:20	How do you focus on the respiratory aspects of a cardiopulmonary case? Paolo Palange (Rome, Italy)
15:50	Discussion and Q&A Speaker to be confirmed
16:00	Break
16:30	Case presentations in cardiopulmonary exercise test interpretation Pierantonio Laveneziana (Paris, France), J. Alberto Neder (Kingston (ON), Canada)

10

5C Session 14:00 - 17:30

Postgraduate course: PG8 Diagnosis and management of sarcoidosis - € Additional registration is required for this session.

Aims: 1. Learn to diagnose pulmonary sarcoidosis using different tools such as imaging, tissue biopsy, biomarkers and become acquainted with the pitfalls during the diagnostic trajectory.

- 2. Increase the knowledge on cardiac sarcoidosis which is one of the leading causes of mortality in sarcoidosis.
- 3. Learn to recognize common symptoms that are not organ-specific in sarcoidosis and their potential treatment options.
- 4. Receive updates on the mechanisms of possible new treatment options for sarcoidosis in the near future.

Disease(s): Interstitial lung diseases

Method(s): General respiratory patient care Imaging

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Nurse, Radiologist, Respiratory therapist

Chairs: Irina Ruxandra Strambu (Bucuresti (Sector 5), Romania), Jacobo Sellares Torres (Barcelona, Spain)

14:00	The patient's perspective on diagnosis and management of sarcoidosis (pre-recorded) Speaker to be confirmed
14:05	Practical aspects in diagnosis and treatment of pulmonary sarcoidosis Florence Jeny (bobigny, France)
14:25	Discussion and Q&A Speaker to be confirmed
14:35	Diagnosis and management of cardiac sarcoidosis: state of the (he)art Vasileios Kouranos (London, United Kingdom)
14:55	Discussion and Q&A Speaker to be confirmed
15:05	Holistic approach to management in sarcoidosis: airy-fairy or necessity? Marcel Veltkamp (De Meern, Netherlands)
15:25	Discussion and Q&A Speaker to be confirmed
15:35	Break
16:00	Back to basic: understanding disease mechanisms as the backbone for emerging treatment options in sarcoidosis Antje Prasse (Hannover, Germany)
16:20	Discussion and Q&A Speaker to be confirmed
16:30	Group assignment: clinical case discussions

3B Session 14:00 - 17:30

Postgraduate course: PG10 Update on the treatment concepts for obstructive sleep apnoea - € Additional registration is required for this session.

Aims: After this session, the participant will be able to understand the available treatment options for obstructive sleep apnoea. The indications, advantages and drawbacks of these different treatment concepts will be explained. The appropriate selection of different treatment modalities will be discussed. Successful therapy and important outcomes of OSA treatment will be explained from the patient's and physician's perspective.

Disease(s): Respiratory critical care | Sleep and breathing disorders

Method(s): General respiratory patient care Physiology Pulmonary rehabilitation

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational)

11

Chairs: Esther Irene Schwarz (Zürich, Switzerland), Elisa Perger (Milano, Italy)

14:00 CPAP: implementation and follow-up strategies integrating new technologies Manuel Sanchez De La Torre (Toledo, Spain)

14:20	Discussion and Q&A Speaker to be confirmed
14:30	Patient selection, outcomes and current gaps for the implementation of non-CPAP treatments Athanasia Pataka (Thessaloniki, Greece)
14:50	Discussion and Q&A Speaker to be confirmed
15:00	Pharmaceutical therapies for OSA, weight loss and residual sleepiness Dries Testelmans (Leuven, Belgium)
15:20	Discussion and Q&A Speaker to be confirmed
15:30	Break
16:00	Successful therapy and important outcomes in OSA: patient's and physician's perspective (pre- recorded) Stefania Redolfi (Cagliari, Italy), Speaker to be confirmed
16:20	Discussion and Q&A Speaker to be confirmed
16:30	Group assignment Speaker to be confirmed

E103/104 Session 14:00 - 17:30

Postgraduate course: PG12 Novel technologies and insights into immune-epithelial interactions in the lung - €

Additional registration is required for this session.

Aims: The aims of this session are (i) to provide participants with examples of novel technologies and analytical tools used to study immune-epithelial interactions in the lung and (ii) to present and discuss new research findings as well as future research questions in this field and how these can be translated towards the clinic

Disease(s): Airway diseases Interstitial lung diseases Respiratory infections

Method(s): Cell and molecular biology

Tag(s): Basic science

Target audience: Clinical researcher, Scientist (basic, translational)

Chairs: Mareike Lehmann (Marburg, Germany), Antonella Dost (Utrecht, Netherlands)

14:00	Introduction Speaker to be confirmed
14:05	Using high-dimensional mass cytometry to uncover emphysema-associated immune changes Padmini P. S. J. Khedoe (Den Haag, Netherlands)
14:25	Discussion and Q&A Speaker to be confirmed
14:35	Understanding the role of macrophages in tissue building, injury, and infection Speaker to be confirmed
14:55	Discussion and Q&A Speaker to be confirmed
15:05	Round table discussions: experience sharing Speaker to be confirmed
15:30	Break
16:00	Using big data to study immune-epithelial cell interactions Marko Nikolic (Cambridge (Cambridgeshire), United Kingdom)
16:20	Discussion and Q&A Speaker to be confirmed

12

16:30	Taking epithelial-immune interactions from bench to bedside Ali Oender Yildirim (Neuherberg, Germany)
16:50	Discussion and Q&A Speaker to be confirmed
17:00	Group assignment: discussion by multiple-choice questions Speaker to be confirmed

14:00 - 17 5B Session

Postgraduate course: PG7 Masterclass in COPD - € Additional registration is required for this session.

Aims: This PG in COPD aims to update the participants on the late findings on COPD pathophysiology, diagnosis, prevention, and treatment.

Disease(s): Airway diseases

Method(s): Public health Pulmonary rehabilitation

Speaker to be confirmed

Speaker to be confirmed

Group assignment

Tag(s): Clinical

16:20

16:30

Target audience: Adult pulmonologist/Clinician, Medical Student, Physician in Pulmonary Training Chairs: Apostolos Bossios (Stockholm, Sweden), Efthymia Papadopoulou (Thessaloniki, Greece)

Underlying inflammation in COPD: a complex puzzle we need to understand 14:00 Daiana Stolz (Freiburg, Germany) Discussion and O&A 14:20 Speaker to be confirmed Stable and exacerbation-prone COPD: identifying, following, and addressing them 14:30 Alexander Mathioudakis (Manchester, United Kingdom) Discussion and O&A 14:50 Speaker to be confirmed Novel therapies for COPD: targeting inflammation in the new Era – how and when 15:00 Dave Singh (Manchester, United Kingdom) Discussion and O&A 15:20 Speaker to be confirmed 15:30 **Break** Improve life of patients with COPD, targeting the lung function and nutrition: rehabilitation 16:00 Frits M.E. Franssen (Maastricht, Netherlands) Discussion and Q&A

Session 14:00 - 17:30 Amtrıum

Postgraduate course: PG11 Severe respiratory infections - € Additional registration is required for this session.

Aims: This postgraduate course aims to provide a comprehensive overview of the diagnosis and management of severe respiratory infections, addressing key challenges and advances in the field. Participants will gain an in-depth understanding of the role of noninvasive diagnostic and monitoring approaches, the appropriate use of corticosteroids, and the specificities of severe infections in immunocompromised patients. A dedicated session will focus on the increasing recognition of invasive aspergillosis in the context of severe viral pneumonia, particularly influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA).

The course will emphasize evidence-based approaches and practical considerations in clinical decision-making, promoting interactive discussions and case-based learning. By the end of the session, participants will be able to integrate current knowledge into their clinical practice, optimize patient outcomes, and engage in multidisciplinary strategies for the management of severe respiratory infections.

13

Disease(s): Respiratory critical care Respiratory infections

Method(s): General respiratory patient care Respiratory intensive care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Patient

Chairs: Claire Andrejak (Amiens, France), Catia Cilloniz Campos (Barcelona, Spain), Chair to be confirmed

14:00	Non invasive methods in respiratory infections James D. Chalmers (Dundee (Angus), United Kingdom)
14:20	Discussion and Q&A Speaker to be confirmed
14:30	The role of corticosteroids in severe respiratory infections Speaker to be confirmed
14:50	Discussion and Q&A Speaker to be confirmed
15:00	Specificities of severe respiratory infections in immunocompromised patients Speaker to be confirmed
15:20	Discussion and Q&A Speaker to be confirmed
15:30	Break
16:00	Invasive aspergillosis in patients with severe viral pneumonia (IAPA and CAPA) Speaker to be confirmed
16:20	Discussion and Q&A Speaker to be confirmed
16:30	Case-based discussions Speaker to be confirmed
17:00	Multiple-choice questions Speaker to be confirmed
17:10	Discussion of controversial statements Speaker to be confirmed
17:20	Experience sharing and best practices Speaker to be confirmed

5A Session 14:00 - 15:30

Language session: Spanish/Portuguese programme 2025

Targeting infections in respiratory diseases. A joint ERS/ALAT/SBPT/SEPAR/SPP session

Aims : the session aims to review the diagnosis, management and prevention of respiratory infections in patients with respiratory diseases. This session will be delivered in Spanish and Portuguese.

14

Disease(s): Airway diseases Interstitial lung diseases Respiratory infections

Method(s): General respiratory patient care

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Patient, Physician in Pulmonary Training

Chairs: Miriam Barrecheguren Fernandez (Barcelona, Spain), Felipe Villar Alvarez (Madrid, Spain)

14:00 Phenotyping exacerbations in asthma and COPD Carlos José Cordeiro Lopes (Lisboa, Portugal)

14:15 New developments in bronchiectasis Speaker to be confirmed

14:30 Infections in diffuse interstitial lung disease
Lorena Itzel Noriega Aguirre (Ciudad de Panamá, Panama)

14:45 Vaccination in chronic respiratory patients

Rosemeri Maurici Da Silva (Florianópolis (SC), Brazil)

15:00 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session <u>14:00 - 15:00</u>

Forum: Paediatric: part 1

Congenital malformations: diagnosis and management

Aims: Joining different perspectives on standard of care and quality of life in rare and complex congenital airway disease. Congenital malformations are relatively rare but there are many open questions in daily clinical life of pediatric pulmonologists. What imaging is the best and when?, how to treat and monitor these children? Is surgery or a wait-and-see approach the right decision and in whom? How should these children been followed up and what may happen in adulthood

Disease(s): Airway diseases Paediatric respiratory diseases

Method(s): Epidemiology General respiratory patient care Imaging

Tag(s): Clinical

Target audience: General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Physician in Pulmonary Training, Radiologist, Respiratory therapist

Chairs: Alexander Möller (Zürich, Switzerland), Deepa Patel (Leicester, United Kingdom)

14:00 Congenital airway malformations - rational imaging

Speaker to be confirmed

14:15 Congenital airway malformations - prognosis and pulmonary montoring

Christophe Delacourt (Paris, France)

14:30 Management of lung disease in children after esophageal atresia repair

Anastassios Koumbourlis (Washington, United States)

14:45 Discussion and Q&A Speaker to be confirmed

G106/107 Session 14:30 - 16:50

Skills workshop: SW2 SW2 - Pulmonary rehabilitation: extending practice to improve health outcomes

Additional registration is required for this session.

Aims: To describe diagnostic methods and interventions that enable phenotyping individuals based on the clinical problems experienced and tailoring the content of pulmonary rehabilitation programmes to deliver a personalised approach; to describe methods of assessing physical activity level and promoting physical activity; to assess patients who may benefit from neuromuscular electrical stimulation, and to be able to apply and progress the treatment; and to describe and evaluate the incorporation of mindfulness-based interventions into pulmonary rehabilitation and their outcomes.

Disease(s): Airway diseases Interstitial lung diseases Pulmonary vascular diseases

Chairs: Alda Marques (Aveiro, Portugal)

14:30 Introduction

Speaker to be confirmed

14:40 Physical activity assessment and intervention

Joana Cruz (Leiria, Portugal)

Neuromuscular electrical stimulation - in who and how?

Lorna Latimer (Leicester, United Kingdom)

How to improve balance and reduce fall in people undergoing pulmonary rehabilitation

Samantha Harrison (Middlesbrough (Stockton-on-Tees), United Kingdom)

14:40 Implementing mindfulness interventions into pulmonary rehabilitation Eleonora Volpato (Milano (MI), Italy)

Elicium 2 Session 16:30 - 17:30

15

Forum: Paediatric: part 3

Prevention of Respiratory Diseases in children

Aims: 1) To review ERS advocacy activities that aim to improve health of children

2) To discuss the health effects of vaping in children and learn how health care workers advocate against this new pandemic 3) To learn the intricate relationship between obesity and respiratory disorders and discuss strategies to prevent and improve obesity

Disease(s): Airway diseases Paediatric respiratory diseases Sleep and breathing disorders

Method(s): Epidemiology General respiratory patient care Public health

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Respiratory therapist, Journalist

Chairs: Alexander Möller (Zürich, Switzerland), Deepa Patel (Leicester, United Kingdom)

16:30	Primary prevention of pediatric lung diseases Monika Gappa (Düsseldorf, Germany)
16:45	Vaping: the new pandemic. What can healthcare professionals do to stop? Sophie Cohen (Amsterdam, Netherlands)
17:00	Prevention of obesity related respiratory disease Stijn Verhulst (Antwerpen, Belgium)
17:15	Discussion and Q&A Speaker to be confirmed

16

G104/105 Session 08:00 - 10:20

Skills workshop: SW3 SW3 - Advanced interpretation of cardiopulmonary exercise testing Additional registration is required for this session.

Aims: Tips and pitfalls in evaluating the pulmonary aspects of cardiopulmonary exercise testing - To identify the typical pulmonary patterns of responses in cardiopulmonary exercise testing, and to develop new skills and expertise to discriminate these from anomalous response profiles, which can cause misinterpretation of test results; to develop skills to correctly assess breathlessness and dynamic hyperinflation.

Disease(s): Airway diseases Interstitial lung diseases Pulmonary vascular diseases

Method(s): Physiology Pulmonary function testing Pulmonary rehabilitation

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Paediatrician, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist

Chairs: Pierantonio Laveneziana (Paris, France)

08:00	Assessing breathlessness Paolo Onorati (Alghero (SS), Italy)
08:00	Laryngoscopy during exercise – Live DEMO James H. Hull (London, United Kingdom), Hege Clemm (Paradis, Norway)
08:00	Ventilatory efficiency and gas exchange Afroditi Boutou (Thessaloniki, Greece)
08:00	Dynamic hyperinflation and other respiratory measurements – live DEMO William Stringer (Long Beach, United States), Mathieu Marillier (Echirolles, France)

7A Session 08:30 - 10:00

Symposium: Long COVID 2025 five years on: where are we and where we need to be Long Covid in 2025

Aims: The aim of this session is to spotlight Long Covid five years after the COVID-19 pandemic started. The aim of the symposium is to provide the latest insights into the underlying pathophysiology, respiratory sequelae such as post-covid interstitial lung disease, therapeutic options including rehabilitation, and healthcare models for people with Long Covid. A theme of the symposium is to provide a global perspective on future directions for research and clinical care for people living with Long Covid.

Disease(s): Interstitial lung diseases Pulmonary vascular diseases Respiratory infections

Method(s): Cell and molecular biology Physiology Pulmonary rehabilitation

Tag(s): Clinical

Target audience : Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

Chairs: Rainer Gloeckl (Schoenau am Koenigssee, Germany)

08:30	Underlying mechanisms of Long Covid: towards a personalised medicine approach for clinical care and trials Rachael A. Evans (Leicester (Leicestershire), United Kingdom)
08:45	Post-COVID lung disease - prevalence, treatment and prognosis in 2025 Speaker to be confirmed
09:00	Rehabilitation for Long COVID and Post-COVID ILD - what do we know in 2025? Tessa Schneeberger (Schönau am Königssee, Germany)
09:15	World Health Organisation Europe: perspective on Long Covid five years on Joan B Soriano (Madrid, Spain)
09:30	Discussion and Q&A Speaker to be confirmed

5A Session 08:30 - 10:00

17

Symposium: Treatment decisions in NTM lung disease: When to start? When to (de)escalate? When to stop? organised by NTMnet

Aims: Non-tuberculous mycobacteria (NTM) are an emerging public health concern: around the globe NTM are increasingly being isolated from respiratory samples associated with a clear rise in prevalence of NTM lung infections. The clinical relevance of this finding may not always be clear and treatment decisions – including when to start as much as when to stop therapy - can be challenging from clinicians and patients. There is a clear need for biomarkers for disease activity and treatment response beyond the microbiological conversion. Last but not least, in NTM-lung disease the host-immune response plays a key role but the knowledge of the human pulmonary immune response to NTM remains however limited. In this symposium we will look beyond the 2020 NTM management guidelines addressing common issues of when to start and when to stop antimicrobial therapy. You will learn the most recent advances in biomarker research for NTM disease activity and treatment response, which can inform treatment decisions. Lastly, you will get the latest insights in host-immune response to NTM and possible translations to host-directed therapies.

Disease(s): Airway diseases Respiratory infections

Method(s): General respiratory patient care Imaging

Tag(s): Clinical, Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Journalist

Chairs: Natalie Lorent (Leuven, Belgium), Giovanni Fumagalli (Milano, Italy)

VOLSU WHEN TO STALL AND INICIONAL THE ADVIN TYLE DE DILLET CHE DEL SPECTIVE	08:30	When to start antimicrobial therapy in NTM-PD? Different perspe	ectives
---	-------	---	---------

08:45	The critical role of the host in NTM disease susceptibility and management Speaker to be confirmed
09:00	Biomarkers for monitoring disease activity and treatment response
09:15	Antimicrobial therapy for NTM lung disease: How long is long enough? Raquel Duarte (Porto, Portugal)
09:30	Discussion and Q&A Speaker to be confirmed

5D Session 08:30 - 10:00

Symposium: Importance of the exposome in prevention and treatment of chronic lung diseases The EXPLAIN inter-assembly collaboration project

Aims: - To define the exposome landscape and its possible risks for human respiratory health

- To summarize and clarify what is already known on the role of exposome in the development of chronic lung diseases including interstitial lung diseases and knowledge gaps still remaining
- To clarify how the exposome plays an important role in the prevention of (the progression of) chronic lung diseases
- To outline the possible influence of the exposome on the early onset of chronic lung diseases
- To discuss how measures to reduce exposome involvement might be useful to treat pediatric and adult chronic lung diseases

Disease(s): Airway diseases Interstitial lung diseases Paediatric respiratory diseases

Method(s): Epidemiology General respiratory patient care Physiology

Tag(s): Translational, Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Scientist (basic, translational), Respiratory therapist

Chairs: Anke-Hilse Maitland-van der Zee (Amsterdam, Netherlands), Agnes Boots (Maastricht, Netherlands)

08:30	Shaping the global exposome landscape from an epidemiological point of view Speaker to be confirmed
08:45	Exposome involvement in early onset of chronic lung diseases Erol Gaillard (Leicester, United Kingdom)
09:00	Mapping and modifying the exposome to prevent chronic lung diseases in a global perspective Hsiao-Chi Chuang (Taipei, Taiwan)
09:15	The role of the exposome in developing and treating ILDs Nikoleta Bizymi (Drafi, Rafina-Pikermi, Attiki, Greece)
09:30	Discussion and Q&A Speaker to be confirmed

5B Session 08:30 - 10:00

18

Symposium: Lung transplantation in 2025 - what's new and on the horizon

Aims: Learn about updates in field of lung transplantation with a focus on recipient selection, donor management, new diagnostic tools and novel therapies.

Disease(s): Interstitial lung diseases

Method(s): Transplantation Tag(s): Clinical, Translational

Target audience: Adult pulmonologist/Clinician, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Thoracic surgeon

Chairs: Federica Meloni (Pavia (PV), Italy), Dorina Esendagli (Ankara, Turkey), Joanna Chorostowska-Wynimko (Warsaw, Poland)

08:3	Updates in donor management Nuria M. Novoa (Majadahonda, Spain)
08:4	New diagnostic and monitoring tools in lung transplant recipients Sameep Sehgal (Cleveland, United States)
09:0	Acute cellular and antibody mediated rejection, immunopathological features and therapeutic implications Speaker to be confirmed
09:1	5 Upcoming therapies for CLAD Caroline Patterson (London, United Kingdom)
00.2	Discussion and Q&A

Session 08:30 - 10:00

Symposium: Nasal high-flow (NHF) – Quo vadis?

Aims: In recent years, a new method of non-invasive respiratory support has been established. Due to the coronavirus pandemic, nasal high-flow ventilation (NHF) has spread rapidly and is now frequently used. However, the significance of NHF in different situations and in comparison to other non-invasive methods of respiratory support is still unclear. The lecture will explore the fundamental physiological effects of NHF, differences between the non-invasive support methods and the significance of NHF for clinical management in different

Disease(s): Airway diseases Respiratory critical care **Method(s):** Physiology Respiratory intensive care

Speaker to be confirmed

Tag(s): Clinical

09:30

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Nurse, Respiratory critical care physician, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Respiratory therapist

Chairs: Christian Karagiannidis (Cologne, Germany), Luk Ping Lam (Hong Kong, Hong Kong)

08:30	Physiological benefits of nasal high-flow: effects in acute and chronic respiratory failure Marieke L. Duiverman (Groningen, Netherlands)
08:45	Nasal high-flow in acute respiratory failure: how does is compare to SOT, CPAP, NIV? Oriol Roca Gas (Barcelona, Spain)
09:00	Nasal high-flow in chronic respiratory failure: what is the evidence? Jens Bräunlich (Leipzig, Germany)
09:15	Nasal high-flow - What comes next? Stefano Nava (Bologna (BO), Italy)
09:30	Discussion and Q&A Speaker to be confirmed

Auditorium Session 08:30 - 10:00

State of the art session: Pulmonary vascular diseases

Pulmonary hypertension associated with lung diseases: the most burning questions

Aims: The aim of this session is to provide an overview on the most actual clinical and translational questions in the field of pulmonary hypertension associated with lung diseases. This should help clinicians in their daily clinical routine management of patients and clinical researchers in order to identify clinically relevant research questions.

19

Method(s): Cell and molecular biology Imaging

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Physician in Pulmonary Training, Radiologist, Scientist (basic,

translational)

Chairs: Christophe Guignabert (Paris, France), Olivier Sitbon (Le Kremlin-Bicêtre, France), Nesrin Öcal (Ankara, Turkey)

dergo right heart

David Kiely (Sheffield (South Yorkshire), United Kingdom)

08:45 PH drugs in the management of PH associated with lung diseases: clinical trials and clinical practice Oksana Shlobin (Falls Church, United States)

09:00 Novel possible treatment approaches of PH associated with lung diseases: a molecular perspective Martin Kolb (Hamilton (ON), Canada)

09:15 Lung phenotype in pulmonary arterial hypertension Marius M. Hoeper (Hannover, Germany)

09:30 Discussion and Q&A Speaker to be confirmed

G106/107 Session 09:00 - 12:30

Skills workshop: SW6 SW6 - Diagnostic techniques in the assessment of sleep-disordered breathing

Additional registration is required for this session.

Aims : Various types of sleep studies with their advantages and disadvantages in the diagnosis of sleep-related breathing disorders are discussed and the interpretation of poly(somno)graphs in adults and children is systematically demonstrated using examples and additionally poly(somno)graphy +/- capnometry under therapy (e.g. CPAP, ASV, NIV) of a sleep-related breathing disorder will be interpreted.

Disease(s): Paediatric respiratory diseases Sleep and breathing disorders

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Physiologist

09:00 Different levels of sleep studies Ding Zou (Gothenburg, Sweden)

09:00 Interpretation of poly(somno)graphy in adult Renata L. Riha (Edinburgh (Edinburgh), United Kingdom)

09:00 Interpretation of polysomnography/polygraphy in children Athanasios G. Kaditis (Athens, Greece)

09:00 Interpretation of sleep studies on positive airway pressure therapy (e.g. CPAP, ASV, NIV)
Athanasia Pataka (Thessaloniki, Greece)

5B Session 10:15 - 11:45

Symposium: Diagnosis of mesothelioma and malignant pleural effusion – the future

Aims: The aims of this symposium are to:

- 1. Review the evidence base for radiological diagnosis and monitoring of malignant effusion and mesothelioma
- 2. Understand the role of ctDNA and molecular techniques in the current diagnosis and management of malignant pleural effusion
- 3. Review the evidence base for optimal diagnostic biopsy method and structured follow up of patients with suspicious pleural lesions
- 4. Understand the role of biomarkers and clinical data in outcome prediction in mesothelioma.

Disease(s): Thoracic oncology

Method(s): Cell and molecular biology Endoscopy and interventional pulmonology General respiratory patient care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Nurse, Pathologist, Radiologist, Thoracic oncologist

Chairs: Federica Meloni (Pavia (PV), Italy), Dorina Esendagli (Ankara, Turkey), Joanna Chorostowska-Wynimko (Warsaw, Poland)

20

10:15	Mesothelioma phenotyping and outcome prediction Speaker to be confirmed
10:30	Modern radiology and the diagnosis of malignant pleural disease Selina Tsim (Glasgow (Glasgow), United Kingdom)
10:45	ctDNA and pleural malignancy diagnosis – ready for the bigtime? Speaker to be confirmed
11:00	Image guided biopsies, thoracoscopy and the negative biopsy – how should we proceed Anand Sundaralingam (Oxford, United Kingdom)
11:15	Discussion and Q&A Speaker to be confirmed

Auditorium Session 10:15 - 11:45

Clinical cases: Lungs on fire: Pulmonary vascular diseases?

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

Disease(s): Pulmonary vascular diseases

Tag(s): Clinical

Chairs: Christophe Guignabert (Paris, France), Olivier Sitbon (Le Kremlin-Bicêtre, France), Nesrin Öcal (Ankara, Turkey)

Discussants: Marion Delcroix (Leuven, Belgium), Gabor Kovacs (Graz, Austria)

10:15 Case 1 incl. panel discussion and Q&A
Marion Delcroix (Leuven, Belgium)

10:37 Case 2 incl. panel discussion and Q&A
Gabor Kovacs (Graz, Austria)

10:59 Case 3 incl. panel discussion and Q&A
Marion Delcroix (Leuven, Belgium)

11:21 Case 4 incl. panel discussion and Q&A
Gabor Kovacs (Graz, Austria)

5C Session 10:15 - 11:45

Mini symposium: Infections in severe respiratory failure

Aims: To discuss Infections in severe respiratory failure especially the importance of influenca and fungal infections in every day clinical practice.

Disease(s): Airway diseases Respiratory critical care Respiratory infections

Method(s): General respiratory patient care Physiology Respiratory intensive care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Respiratory therapist

21

Chairs: Christian Karagiannidis (Cologne, Germany), Luk Ping Lam (Hong Kong, Hong Kong)

10:15 Understanding the alveolar host response in ARDS and pneumonia

- 10:30 Bacterial superinfections in viral pneumonia Ignacio Martin-Loeches (Dublin, Ireland)
- 10:45 Fungal infections in non-resolving ARDS

Speaker to be confirmed

11:00 Discussion and Q&A Speaker to be confirmed

5D Session 10:15 - 11:45

Mini symposium: Forewarned is forearmed: cohort studies in the mission to understand structural and immunological determinants of early disease in COPD.

Aims: This mini symposium aims to summarise highlights from longitudinal cohort studies, providing insight into the structural and immunological features of early disease manifestations in COPD. Attendees will gain insights into potential mechanisms implicated in early disease, how these manifest in terms of clinical presentation and some potential avenues for early screening and intervention.

Disease(s): Airway diseases

Method(s): Cell and molecular biology General respiratory patient care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Nurse, Physiologist, Respiratory physiotherapist

Chairs: Anke-Hilse Maitland-van der Zee (Amsterdam, Netherlands), Agnes Boots (Maastricht, Netherlands)

10:15 Preterm birth, bronchopulmonary dysplasia, and development of lung function; a road to COPD?

Speaker to be confirmed

Early identification of airway diseases: Results from the The Undiagnosed COPD and Asthma
Population (UCAP) trial and beyond
Shawn Aaron (Ottawa (ON), Canada)

11:00 Clinical prognosis for young tobacco smokers: Results from the Copenhagen City Heart Study Yunus Çolak (Espergærde, Denmark)

11:15 Discussion and Q&A Speaker to be confirmed

G104/105 Session 10:40 - 13:00

Skills workshop: SW4 SW4 - Advanced interpretation of cardiopulmonary exercise testing Additional registration is required for this session.

Aims: Tips and pitfalls in evaluating the pulmonary aspects of cardiopulmonary exercise testing - To identify the typical pulmonary patterns of responses in cardiopulmonary exercise testing, and to develop new skills and expertise to discriminate these from anomalous response profiles, which can cause misinterpretation of test results; to develop skills to correctly assess breathlessness and dynamic hyperinflation.

Disease(s): Airway diseases Interstitial lung diseases Pulmonary vascular diseases

Chairs: Mathieu Marillier (Echirolles, France)

10:40 Assessing breathlessness
Michele Schaeffer (Vancouver, Canada)

10:40 Laryngoscopy during exercise – Live DEMO
James H. Hull (London, United Kingdom), Hayley Lewthwaite (Merewether, Australia)

10:40 Ventilatory efficiency and gas exchange

10:40 Dynamic hyperinflation and other respiratory measurements – live DEMO Pierantonio Laveneziana (Paris, France), Afroditi Boutou (Thessaloniki, Greece)

Forum Session 12:45 - 13:45

Joint session: A Year-in-Review in Bronchiectasis

J. Alberto Neder (Kingston (ON), Canada)

Aims: - Deliver a Comprehensive Update: To provide a detailed overview of the most significant advancements in bronchiectasis research, diagnostics, and management over the past year, with input from both academic and industry perspectives.

- Showcase Key Developments: To highlight breakthroughs in understanding the pathophysiology of bronchiectasis, alongside cutting -edge diagnostic approaches and innovative therapeutic strategies, developed through academic-industry collaboration.
- Bridge Research, Industry, and Practice: To explore how the latest findings and technologies can be effectively translated into clinical practice, with a focus on improving patient outcomes and addressing real-world challenges.

22

- Shape Future Directions Together: To identify priorities for future research and development, fostering dialogue and collaboration between academic researchers, healthcare professionals, and industry stakeholders.

Disease(s): Airway diseases Paediatric respiratory diseases Respiratory infections

Method(s): Cell and molecular biology Epidemiology Pulmonary rehabilitation

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

Chairs: James D. Chalmers (Dundee (Angus), United Kingdom), Michal Shteinberg (Haifa, Israel)

12.45	Initial Assessment of Bronchiectasis
12:45	0 1 4 1 6 1

Speaker to be confirmed

Treating Bronchiectasis in a Stable State 13:00 Michael Loebinger (London, United Kingdom)

Treating Exacerbations of Bronchiectasis 13:15

Speaker to be confirmed

Discussion and Q&A 13:30 Speaker to be confirmed

Session

Symposium: A new era of endobronchial ultrasound and imaging in staging and treatment of lung cancer from global perspective

Aims: Endobronchial ultrasound (EBUS) is a well-established method for staging and diagnosing lung cancer. However, we are entering a phase that will bring significant changes to clinical practice. Over the next year, new EBUS guidelines will be published, and the 9th classification of lung cancer is expected, which will further subdivide the N2 stage into categories a and b. Recent studies, particularly the SEIZMIC trial, emphasize the benefits of systematic mediastinal staging in locally advanced lung cancer for accurate radiotherapy planning — an approach not commonly used in the past. Furthermore, there have been significant improvements in patient survival thanks to neoadjuvant chemoimmunotherapy in operable stages of lung cancer. From EBUS procedures is from now on expected not only more precise N1 staging but also tissue sampling for biomarker analysis.

Additionally, response to new treatment of LC and possible complications in imaging studies will be discussed. At last but not least,

differences in LC diagnosis and treatment in MLIC will be pointed out

Disease(s): Thoracic oncology

Method(s): Endoscopy and interventional pulmonology Imaging

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Pathologist, Physician in Pulmonary Training, Radiologist, Thoracic oncologist, Thoracic surgeon

Chairs: Marjolein A. Heuvelmans (Amsterdam, Netherlands), Walter De Wever (Leuven, Belgium), Amanda Dandanell Juul (Odense S, Denmark)

What are new needs in clinical practice for lung cancer diagnosis and staging in the light of updated 9th 13:45

TNM edition for classification of lung cancer

António Alexandre Pinto Bugalho De Almeida (Lisboa, Portugal)

New requirements in staging and restaging of mediastinum and lung cancer introduced by guided 14:00 radiotherapy and neoadjuvant chemoimmunotherapy

Ales Rozman (Golnik, Slovenia)

Role of imaging in assessment of treatment response and complication in patients undergoing new lung

14:15 cancer therapies

Speaker to be confirmed

Obstacles, limitations and challenges in lung cancer diagnosis and management in LMIC- differences

14:30 and similarities?

Speaker to be confirmed

Discussion and O&A 14:45 Speaker to be confirmed

Session

23

Symposium: Natural and Man-Made Disasters: a New Global Norm?

Aims: 1. Present the range of natural and man-made inhalational disasters that are presenting to physicians in general, and respiratory health care professionals in particular.

2. Identify the range of effects observed acutely and chronically in those affected.

3. Identify the elements of a cohesive response, first and foremost from the perspective of the respiratory health care professionals.

Disease(s): Airway diseases Respiratory critical care Respiratory infections

Method(s): Epidemiology Public health Respiratory intensive care

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Respiratory therapist

Chairs: Rafael E. de la Hoz (New York, United States), Ane Johannessen (Bergen, Norway), Chair to be confirmed

13:45 Airway and Psychological Effects of Inhalation Injuries in Victims and Responders Christopher Carlsten (Vancouver (BC), Canada)

14:00 Climate change, wildfires and respiratory health – population level perspectives Fay Johnston (Hobart, Australia)

14:15 Toxic Inhalation Injuries: Clinical Experience in Turkey Metin Akgün (Erzurum, Turkey)

14:30 Hospital management of severe respiratory injuries in inhalational disasters Raquel Duarte (Porto, Portugal)

14:45 Discussion and Q&A Speaker to be confirmed

5D Session 13:45 - 15:15

Year in review: Scientific

Aims: This session aims to provide an overview of basic and translational scientific highlights and major achievements in the respiratory field within the past year, focusing on novel insights on interactions of structural lung cells within their environment, including mechanical aspects and interactions with immune cells obtained by innovative technologies such as spatial transcriptomics and proteomics. The goal of this session is to provide the audience with an overview of various key publications that are expected to have major impact in the respiratory field, with high relevance for the clinic based on promising results in pre-clinical models. A variety of pulmonary diseases will be covered, including asthma, BPD, COPD, lung fibrosis and respiratory infections, and the potential of translation of novel therapeutic strategies into the clinic will be discussed.

Disease(s): Airway diseases Interstitial lung diseases Paediatric respiratory diseases

Method(s): Cell and molecular biology

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Paediatrician, Scientist (basic, translational)

Chairs: H. Irene Heijink (Groningen, Netherlands), Neeloffer Mookherjee (Winnipeg (MB), Canada), Theodore Kapellos (Munich, Germany)

13:45 Profiling the spatial transcriptome and proteome in lung tissue Speaker to be confirmed

14:00 Regulation of alveolar epithelial and mesenchymal responses by macrophages upon lung tissue injury Speaker to be confirmed

14:15 Mechanosensing and abnormal epithelial damage and repair in respiratory disease Jody Rosenblatt (London, United Kingdom)

14:30 Single-Cell RNA Sequencing to Guide Cell-Based Therapy Speaker to be confirmed

14:45 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session 13:45 - 15:15

24

State of the art session: Paediatric

Aims: To discuss important topics in paediatric respiratory medicine. Post-infective bronchiolitis obliterans (PIBO), is rare but leads to life-long respiratory impairment and hence, early recognition and effective supportive therapies are crucial in the management. Prematurity-associated respiratory disease is a topic that is very relevant not only for pediatric pulmonologists but more and more also for adult specialists. Advanced interventional bronchoscopy is becoming more and more important in the paediatric field and opens new opportunities in the management of children with complex airway diseases. Severe and difficult-to- treat asthma is a continuous hot topic and biologics are becoming more and more popular. However, there are many open questions on how to use these treatment options on the longer term.

Disease(s): Airway diseases Paediatric respiratory diseases Sleep and breathing disorders

Method(s): Endoscopy and interventional pulmonology Epidemiology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

Chairs: Alexander Möller (Zürich, Switzerland), Alice Hadchouel-Duvergé (Paris, France), Monika Gappa (Düsseldorf, Germany)

13:45	Post-infective bronchiolitis obliterans (PIBO) Speaker to be confirmed
14:00	Phenotype based treatment of prematurity-associated respiratory disease Marielle Pijnenburg (Rotterdam, Netherlands)
14:15	Advanced pediatric interventional bronchoscopy with a focus cryotherapy Dirk Schramm (Düsseldorf, Germany)
1120	Asthma biologics: which to use for which patient? When to switch? When to wean/ston?

14:30 Asthma biologics: which to use for which patient? When to switch? When to wean/stop? Sejal Saglani (London, United Kingdom)

14:45 Discussion and Q&A Speaker to be confirmed

G106/107 Session 14:00 - 17:30

Skills workshop: SW7 SW7 - Diagnostic techniques in the assessment of sleep-disordered breathing

Additional registration is required for this session.

Aims: Various types of sleep studies with their advantages and disadvantages in the diagnosis of sleep-related breathing disorders are discussed and the interpretation of poly(somno)graphs in adults and children is systematically demonstrated using examples and additionally poly(somno)graphy +/- capnometry under therapy (e.g. CPAP, ASV, NIV) of a sleep-related breathing disorder will be interpreted.

Disease(s): Paediatric respiratory diseases Sleep and breathing disorders

Tag(s): Clinical

14:00 Different levels of sleep studies Ludger Grote (Göteborg, Sweden)

14:00 Interpretation of poly(somno)graphy in adult Carolina Lombardi (Milano (MI), Italy)

14:00 Interpretation of polysomnography/polygraphy in children Refika Hamutcu Ersu (Ottawa, Canada)

14:00 Interpretation of sleep studies on positive airway pressure therapy (e.g. CPAP, ASV, NIV)
Alexandros Kalkanis (Leuven, Belgium)

G104/105 Session 14:30 - 16:50

Skills workshop: SW5 SW5 - Advanced interpretation of cardiopulmonary exercise testing Additional registration is required for this session.

Aims: Tips and pitfalls in evaluating the pulmonary aspects of cardiopulmonary exercise testing - To identify the typical pulmonary patterns of responses in cardiopulmonary exercise testing, and to develop new skills and expertise to discriminate these from anomalous response profiles, which can cause misinterpretation of test results; to develop skills to correctly assess breathlessness and dynamic hyperinflation.

25

Disease(s): Airway diseases Interstitial lung diseases Pulmonary vascular diseases

Chairs: William Stringer (Long Beach, United States)

14:30	Assessing breathlessness J. Alberto Neder (Kingston (ON), Canada)
14:30	Laryngoscopy during exercise – Live DEMO Hege Clemm (Paradis, Norway), Hayley Lewthwaite (Merewether, Australia)
14:30	Ventilatory efficiency and gas exchange Pierantonio Laveneziana (Paris, France)
14:30	Dynamic hyperinflation and other respiratory measurements – live DEMO Paolo Palange (Rome, Italy), Michele Schaeffer (Vancouver, Canada)

5D Session 15:30 - 17:00

Symposium: A breath of diversity: Impact of biological sex on cellular and molecular mechanisms in respiratory disease

Translational science session

Aims: To enhance the understanding of the influence of biological sex on (1) metabolism processes and immune response in driving sex dimorphism in respiratory disease. (2) Role of sex steroids (hormones) and chromosomes in respiratory disease. (3) Sex-related differences in proteins, signaling pathways and epigenetics in respiratory disease. (4) Sex-related differences in cellular crosstalk in respiratory disease.

Disease(s): Airway diseases Paediatric respiratory diseases Respiratory infections

Method(s): Cell and molecular biology

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Paediatrician, Pathologist

Chairs: H. Irene Heijink (Groningen, Netherlands), Neeloffer Mookherjee (Winnipeg (MB), Canada), Theodore Kapellos (Munich, Germany)

Role of sex hormones in modifying immunometabolism, focusing on Th17 and IL-33 mediated airway inflammation
Dawn Newcomb (Nashville, United States)

- 15:45 Mechanisms of sexual dimorphism in cystic fibrosis
- 16:15 Implications of sex differences for clinical phenotyping and treatment of asthma and COPD Maarten van den Berge (Groningen, Netherlands)
- 16:00 STARSHIP Study of therapeutic trials of sex hormone supplementation in ILD Speaker to be confirmed
- 16:15 Discussion and Q&A Speaker to be confirmed

7A Session 15:30 - 17:00

State of the art session: Sleep and breathing disorders Central sleep apnoea – from pathophysiology over phenotypes to updated treatment recommendations. New recommendations for the teatment of CSA/CSR

Aims: There are new randomised controlled and other prospective studies on the different groups of celiac sleep apnoea syndromes, which make it necessary to revise the previous recommendations and which will change our practice. A new ERS statement on the treatment of CSA with adaptive servoventilation will be presented and the new treatment options for CSA in 2025 will be discussed. After this session, listeners should be up to date in this changing field and thus be able to treat their patients with CSA optimally.

Disease(s): Pulmonary vascular diseases Sleep and breathing disorders

Method(s): General respiratory patient care Physiology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory therapist

26

Chairs: Sophia E. Schiza (Heraklion, Greece), Matteo SICILIANO (ROMA, Italy)

15:30 Understanding pathophysiology of CSA as the basis for treatment selection Winfried J. Randerath (Solingen, Germany)

15:45 New ERS statement on the treatment of CSA with adaptive servo-ventilation Esther Irene Schwarz (Zürich, Switzerland)

16:00	Managing treatment-emergent central sleep apnoea – when and how? Raphael Heinzer (Lausanne, Switzerland)
16:15	New interventional studies in other forms of central sleep apnoea Johan Verbraecken (Edegem (Antwerp), Belgium)
16:30	Discussion and Q&A Speaker to be confirmed

5A Session 15:30 - 17:00

Clinical cases: The world of imaging: working together

Aims: Imaging can be used not only for diagnostic purposes but also for guiding more interventional procedures. These procedures can be performed by radiologists, clinicians, surgeons....

The diaphragm is a region that is often overlooked. However, also there we can find pathology. There are dedicated imaging techniques that can be used to evaluate the diaphragm.

Imaging cases will illustrate the use of these imaging techniques in these settings.

Disease(s): Respiratory critical care Respiratory infections Thoracic oncology

Method(s): Endoscopy and interventional pulmonology Imaging

Tag(s): Clinical

Target audience : Adult pulmonologist/Clinician, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Thoracic oncologist, Thoracic surgeon, Respiratory therapist

Chairs: Marjolein A. Heuvelmans (Amsterdam, Netherlands), Walter De Wever (Leuven, Belgium), Amanda Dandanell Juul (Odense S, Denmark)

15:30	Non-Endoscopic-Ultrasound guided thoracic intervention. Maged Hassan (Alexandria, Egypt)
15:52	Computed tomography guided thoracic intervention Helmut Prosch (Wien, Austria)
16:14	Morphological and functional imaging of the diaphragm Speaker to be confirmed
16:36	CT-guided endoscopy Erik H.F.M. van der Heijden (Nijmegen, Netherlands)

Elicium 2 Session 15:30 - 17:00

Clinical cases: Lungs on fire: Paediatric respiratory diseases

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

Disease(s): Paediatric respiratory diseases

Tag(s): Clinical

Chairs: Alexander Möller (Zürich, Switzerland), Alice Hadchouel-Duvergé (Paris, France), Monika Gappa (Düsseldorf, Germany)

Discussants: Angela Zacharasiewicz (Wien, Austria), Erol Gaillard (Leicester, United Kingdom)

15:30	Case 1 incl. panel discussion and Q&A Angela Zacharasiewicz (Wien, Austria)
15:52	Case 2 incl. panel discussion and Q&A Erol Gaillard (Leicester, United Kingdom)
16:14	Case 3 incl. panel discussion and Q&A Angela Zacharasiewicz (Wien, Austria)
16:36	Case 4 incl. panel discussion and Q&A Erol Gaillard (Leicester, United Kingdom)

27

5C Session

Mini symposium: A Global Perspective on Occupational Lung Disease: moving from diagnosis to

Aims: Highlight the global burden of occupational lung disease through a focus on silicosis and tuberculosis, occupational asthma, byssinosis, and the sequelae of occupational lung disease in Asia and Africa - Describe regional differences and the impact of occupational lung disease on low- and middle-income countries, thereby raising the profile of occupational lung disease in these countries. - B y showcasing interventional trials of workplace educational interventions for Byssinosis and pulmonary rehabilitation for miners with silicotuberculosis, we will successful examples of interventions that mitigate occupational lung disease risks. - Promote global collaboration in occupational lung disease research by emphasising the benefits of international partnerships in advancing research and sharing data, especially in under-resourced settings. - Our recommended panel of Prof Jill Murray (SA) and Dr Dingani Moyo (Zim) would provide a positive and constructive environment for Early Career Researchers to present their work, alongside our expert presenters, and contribute to discussions on occupational lung diseases. Networking opportunities will provide a platform for global collaboration.

Disease(s): Airway diseases Interstitial lung diseases Respiratory infections

Method(s): Epidemiology Public health

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Patient, Physician in Pulmonary Training, Journalist

Chairs: Rafael E. de la Hoz (New York, United States), Ane Johannessen (Bergen, Norway), Chair to be confirmed

Silicosis and Tuberculosis among small-scale miners. 15:30 Patrick Howlett (LONDON, United Kingdom) Reducing the respiratory effects of cotton dust exposure among textile workers 15:45 Asaad Ahmed Nafees (Karachi, Pakistan) Work-related asthma in low and middle income countries 16:00 Mohamed Fareed Jeebhay (Cape Town, South Africa) 16:15

28

Discussion and Q&A Speaker to be confirmed

G104/105 Session 08:00 - 10:20

Skills workshop: SW8 SW8 - Practicalities of pulmonary function testing: spirometry, whole-body plethysmography and diffusion

Additional registration is required for this session.

Aims: This skills workshop will help attendees gain the technical expertise needed to perform spirometry, whole body plethysmography and diffusion test according to both best practice and the latest recommendations that are supported by experts in the field; to understand the measurement principles and technical aspects of spirometry, static lung volumes, airway resistance and diffusion capacity of the lungs; and to learn about the standardisation of test performance, reporting and case study interpretation.

Disease(s): Airway diseases Paediatric respiratory diseases

Method(s): Physiology Pulmonary function testing

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Paediatrician, Physician in Pulmonary Training, Physiologist

Chairs: Rachel Ong-Salvador (Amsterdam, Netherlands)

08:00 Performing Spirometry Lindsay Zurba (Durban, South Africa)

Standardised static lung volume measurement and airways resistance using whole body plethysmography

Aisling McGowan (Dublin 15, Ireland)

08:00 Measurement of the diffusing capacity of the lungs for carbon monoxide using the single-breath method Frans H.C. De Jongh (Enschede, Netherlands)

08:00 Reporting and interpretation of case studies Gregory King (Sydney (NSW), Australia)

5C Session 08:30 - 10:00

Symposium: From wounds to wrinkles: Injuries in life as predictors of lung ageing

Aims: Lung ageing is closely associated with the development of chronic lung diseases, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Ageing is a progressive process whose progression is largely driven by an imbalance in the cellular stress response and the loss of lung intrinsic resilience and regenerative capacity. Depending on the interplay between the lungs and the environment, the processes of ageing can be activated prematurely at an accelerated rate and premature ageing can occur. Susceptibility to damaging factors is not only high with advancing age, but also during critical developmental windows. The concept of Developmental Origins of Health and Disease (DOHaD) states that early adverse influences in life determine lung structural function and thus lifelong health. Interestingly, many lung diseases with developmental origins share similar structural changes as age-associated diseases. Inflammation is an essential underlying molecular mechanism of premature aging (inlfammaging). The proposed symposium will shed light on accelerated lung aging and the risk for chronic lung disease across the entire life span, ranging from the intrauterine/perinatal and preconception period to aging humans. Among others, we want to address the following knowledge gaps: "When does aging begin?", "How does inflammation trigger onset and progression of chronic lung disease at different stages of life" and "How to maintain lung resilience and promote regeneration".

To this end, we will line up speakers across different expertise, ranging from epidemiology, developmental biology, pediatric/ neonatal lung biology and medicine, adult chronic lung diseases, to regenerative lung biology and medicine.

At the conclusion of this session, the attendant will be able to explain the developmental origins of chronic lung diseases and how to use current advanced technologies to delineate premature aging processes. The attendant will furthermore be able to discuss ways to promote lung intrinsic regenerative resources. The session chairs will evaluate these outcomes by audience response and feedback. A successful session will encourage basic, clinical, and translational research that will bridge knowledge gaps at the intersection of translational lung research aiming to understand pathological mechanisms and the development of more effective stratification of patients and subsequent therapeutic strategies for CLDs that are a major global health burden.

29

Disease(s): Airway diseases Interstitial lung diseases Paediatric respiratory diseases

Method(s): Cell and molecular biology Epidemiology Pulmonary function testing

Tag(s): Translational, Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Paediatrician, Patient, Scientist (basic, translational)

Chairs: Silke Meiners (Sülfeld, Germany), Didier Cataldo (Liege, Belgium), Sara Cuevas Ocaña (Jaen, Spain)

08:30 Immune changes over the lifespan - challenges across the Globe Speaker to be confirmed

08:45 From uterus to lung disease: Intergenerational triggers of premature lung inflamm-aging Miguel Angel Alejandre Alcázar (Cologne, Germany)

09:00	Ticking together: Epigenetic clock ad lung aging across the lifespan Morten Scheibye-Knudsen (Copenhagen, Denmark)
09:15	Turning back the clock: How to target aging in the lung Mareike Lehmann (Marburg, Germany)
09:30	Discussion and Q&A Speaker to be confirmed

5A Session 08:30 - 10:00

State of the art session: Thoracic oncology LUNG CANCER SCREENING UPDATES; SWITCH GEARS TO MOVE FORWARD

Aims: Lung cancer screening is an emerging field of major clinical interest aiming to reduce lung cancer related mortality significantly. Many countries around the world are in the process of implementing/planning lung cancer screening programmes aiming to address their diverse needs. The ERS is a key stakeholder involved in impactful paneuropean projects aiming to streamline lung cancer screening pathways and processes and improve clinical outcomes. This session aims to (1) Describe recent updates on the existing ERS led projects (EU funded) in lung cancer screening (SOLACE, IDERHA, OPTIMA) (2) Analyze best practices and pitfalls in LCS programmes worldwide (3) Analyze the LCS screening curriculum proposed by the ERS (4) Evaluate interrelations between biomarkers and ERS led lung cancer screening projects. (5) Assess existing experience and troubleshooting towards a pragmatic implementation of LCS programmes in a real clinical setting.

Disease(s): Thoracic oncology

Method(s): Endoscopy and interventional pulmonology Imaging Surgery

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Respiratory therapist, Journalist

Chairs: Wouter H. van Geffen (Leeuwarden, Netherlands), marcello migliore (Catania, Italy), Andriani Charpidou (Athens, Greece)

08:30	Enhanced patient access to lung cancer screening Torsten Gerriet Blum (Berlin, Germany)
08:45	Biomarkers in lung cancer screening selection, risk stratification and prognosis
09:00	Best practices, pitfalls and troubleshooting in lung cancer screening programmes worldwide; the current state of play Martina Koziar Vasakova (Praha 10, Czech Republic)
09:15	Developing a lung cancer screening curriculum for healthcare professionals Georgia Hardavella (Athens, Greece)
09:30	Discussion and Q&A Speaker to be confirmed

Auditorium Session 08:30 - 10:00

State of the art session: Interstitial lung diseases Horizon scanning in the treatment of Interstitial Lung Diseases

Aims : To describe the bench to bedside approach in the development of therapies for Interstitial Lung disease To highlight the emerging therapeutic interventions for the management of Interstitial Lung Diseases

To describe the non-pharmacological approaches in the management of ILDs

To explore the lessons learnt from other organ systems with respect to pathophysiology of pulmonary fibrosis

Disease(s): Interstitial lung diseases

Method(s): Cell and molecular biology Epidemiology General respiratory patient care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Scientist (basic, translational), Respiratory therapist

30

Chairs: Nazia Chaudhuri (Limavady, United Kingdom), Wim A. Wuyts (Leuven, Belgium), Michael Kreuter (Mainz, Germany)

From bench to bedside: How advancements in scientific knowledge leads to new therapies in pulmonary fibrosis

Speaker to be confirmed

08:45 Emerging pharmacological therapies in Interstitial Lung Diseases

Non-pharmacological strategies to impact quality of life in Interstitial Lung Diseases
Sabina A. Guler (Bern, Switzerland)

What can we learn from fibrosis in other organ systems eg kidney, liver and heart?
ARGYRIS TZOUVELEKIS (Patras, Greece)

Discussion and Q&A
Speakers to ke are formed.

5D Session 08:30 - 10:00

Mini symposium: Primary pulmonary lymphomas: a wide spectrum of disguising entities Primary pulmonary lymphomas

Aims: Identification of primary pulmonary lymphomas according to the recent WHO classification,

Description of the peculiar or disguising clinical/laboratory profile by which they may manifest and discussion of fundamental pathogenetic aspects

Imaging documentation of parenchymal/pleural involvement taking into account also new techniques such as photon.counting CT and nuclear medicine

Finally presentation mainly of endoscopic or other mini.invasive approaches along with sophisticated laboratory tests that may confirm the diagnosis

Differential diagnoses or tricks will be part of the presentation by each speaker

Disease(s): Interstitial lung diseases Thoracic oncology

Speaker to be confirmed

Method(s): Cell and molecular biology Endoscopy and interventional pulmonology Imaging

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon

Chairs: Sara Piciucchi (Forlì, Italy)

O8:30 Clinical overview
Yurdagül Uzunhan (Bobigny, France)

O8:45 Pulmonary lymphomas: a challenge for the radiologist
Speaker to be confirmed

O9:00 Mini-invasive approach to lymphoproliferative disease: is cryobiopsy enough?
Venerino Poletti (Forlì, Italy)

O9:15 Discussion and Q&A
Speaker to be confirmed

Elicium 2 Session 10:15 - 11:45

Symposium: COPD and T2 inflammation - is it really a treatable trait?

Aims: While it has been long-recognised that COPD is an inflammatory lung disease, dissimilar to asthma, type 2 inflammation was thought to play a minor role. However, recent studies suggest that in approximately one third of patients with COPD, type 2 inflammation may be an important driver of disease and a potential therapeutic target. Importantly, the immune cells and molecules involved in COPD-related type 2 immunity may be significantly different from those observed in severe asthma. Here, we discuss the recent findings on Th2 inflammation in COPD and explore the future of therapeutic development of type 2 immune modulators in COPD.

Disease(s): Airway diseases Respiratory critical care Respiratory infections

Method(s): Cell and molecular biology Epidemiology Imaging

Tag(s): Translational

Target audience : Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

Chairs: Francesca Polverino (Houston, United States), Augusta Beech (Manchester, United Kingdom), Apostolos Bossios (Stockholm, Sweden)

31

10:15 COPD: pathobiological features supporting the case for a T2 trait Speaker to be confirmed

10:30 Eosinophilic COPD: is it just asthma? evidence from the clinic and trials. Johann Christian Virchow (Rostock, Germany)

Beyond eosinophils and T2:conventional culprits and targets in COPD biology. 10:45

Hsiao-Chi Chuang (Taipei, Taiwan)

COPD current and future therapeutic targets:insights from clinical trials. 11:00

Mona Bafadhel (London, United Kingdom)

Discussion and O&A 11:15 Speaker to be confirmed

10:15 - 11:4 Session

Journal session: The best of the European Respiratory Journal 2025

Aims: To highlight the key studies published in 2024-2025 in the fields of

- Pulmonary vascular disease
- Interstitial lung disease
- Paediatrics
- Airways diseases

Disease(s): Airway diseases Interstitial lung diseases Paediatric respiratory diseases

Method(s): General respiratory patient care Public health

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Scientist (basic, translational), Respiratory therapist

Chairs: James D. Chalmers (Dundee (Angus), United Kingdom), Myrofora Goutaki (Bern, Switzerland), Chiara Premuda (Palermo, Italy)

The best of the ERJ- Pulmonary vascular diseases 10:15

Marc Humbert (Le Kremlin-Bicêtre, France)

- The best of the ERJ- Interstitial Lung Disease 10:30
 - Marlies S. Wijsenbeek (Rotterdam, Netherlands)
- The best of the ERJ- Paediatric pulmonology 10:45
 - Claudia E. Kuehni (Bern, Switzerland)
- The best of the ERJ- Airways Diseases 11:00
 - Donald Sin (Vancouver (BC), Canada)
- Discussion and Q&A 11:15 Speaker to be confirmed

Session

Clinical cases: Lungs on fire: Lung cancer?

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

Disease(s): Thoracic oncology

Tag(s): Clinical

Chairs: Wouter H. van Geffen (Leeuwarden, Netherlands), marcello migliore (Catania, Italy), Andriani Charpidou (Athens, Greece)

32

Discussants: Najib M. Rahman (Oxford, United Kingdom), Discussant to be confirmed

Case 1 incl. panel discussion and Q&A 10:15

Speaker to be confirmed

- Case 2 incl. panel discussion and Q&A 10:37
 - Najib M. Rahman (Oxford, United Kingdom)
- Case 3 incl. panel discussion and Q&A 10:59 Speaker to be confirmed
- Case 4 incl. panel discussion and O&A 11:21 Najib M. Rahman (Oxford, United Kingdom)

Auditorium Session 10:15 - 11:45

Clinical cases: Lungs on fire: Interstitial lung diseases?

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

Disease(s): Interstitial lung diseases

Tag(s): Clinical

Chairs: Nazia Chaudhuri (Limavady, United Kingdom), Wim A. Wuyts (Leuven, Belgium), Michael Kreuter (Mainz, Germany)

Discussants: Pilar Rivera Ortega (Exeter, United Kingdom), Vincent Cottin (Lyon, France)

10:15 Case 1 incl. panel discussion and Q&A
Pilar Rivera Ortega (Exeter, United Kingdom)

10:37 Case 2 incl. panel discussion and Q&A Vincent Cottin (Lyon, France)

10:59 Case 3 incl. panel discussion and Q&A Pilar Rivera Ortega (Exeter, United Kingdom)

11:21 Case 4 incl. panel discussion and Q&A Vincent Cottin (Lyon, France)

G104/105 Session 10:40 - 13:00

Skills workshop: SW9 SW9 - Practicalities of pulmonary function testing: spirometry, whole-body plethysmography and diffusion

Additional registration is required for this session.

Aims: This skills workshop will help attendees gain the technical expertise needed to perform spirometry, whole body plethysmography and diffusion test according to both best practice and the latest recommendations that are supported by experts in the field; to understand the measurement principles and technical aspects of spirometry, static lung volumes, airway resistance and diffusion capacity of the lungs; and to learn about the standardisation of test performance, reporting and case study interpretation.

Disease(s): Airway diseases Paediatric respiratory diseases

Chairs: Kathryn Ramsey (Perth (WA), Australia)

10:40 Performing Spirometry Jana Kivastik (Tartu, Estonia)

Standardised static lung volume measurement and airways resistance using whole body plethysmography

Matthew Rutter (Cambridge (Cambridgeshire), United Kingdom)

10:40 Measurement of the diffusing capacity of the lungs for carbon monoxide using the single-breath method Monique Wapenaar - De Korver (Vlaardingen, Netherlands)

10:40 Reporting and interpretation of case studies
Maximillian Thomas (Birmingham, United Kingdom)

G106/107 Session 10:40 - 13:00

Skills workshop: SW11 SW11 - Practical Pulmonary Hypertension Additional registration is required for this session.

Aims: 1. Develop a practical approach to investigating and diagnosing PH

- 2. Develop a systematic approach to interpreting radiological investigations
- 3. Understand the 4 main echo views and important features of PH at echocardiography including hands-on experience with PH patients and healthy volunteers
- 4. Understand the pathological changes associated with different forms of PH and appreciate how these translate into clinical phenotypes
- 5. Understand right heart catheterization and be able to incorporate clinical, radiological and haemodynamic features to make the correct diagnosis

33

Disease(s): Pulmonary vascular diseases

Method(s): General respiratory patient care Imaging

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Respiratory critical care physician, Pathologist, Physician in Pulmonary Training,

Radiologist

Chairs: Robin Condliffe (Sheffield (South Yorkshire), United Kingdom)

10:40	Radiological assessment of pulmonary hypertension
10.10	Lilian Meijhoom (Amsterdam, Netherlands)

Lilian Meijboom (Amsterdam, Netherlands)

Pathological assessment of pulmonary hypertension

Peter Dorfmüller (Giessen, Germany)

10:40 Echocardiography in pulmonary hypertension

Marielle van de Veerdonk (Amsterdam, Netherlands)

10:40 Clinical assessment of pulmonary hypertension

Esther Nossent (Amsterdam, Netherlands)

Forum Session 12:45 - 13:45

Joint session: Vaccination: Who, When and What?

Aims: This session aims to provide a comprehensive understanding of the critical factors involved in designing and implementing effective vaccination strategies for respiratory infections. By addressing the timing of vaccination, the roles of multidisciplinary teams, innovations in vaccine technology, and strategies to increase compliance, the session will equip healthcare professionals with actionable insights to enhance vaccination uptake and effectiveness.

This session will provide attendees with practical tools and knowledge to support the implementation of innovative and inclusive vaccination strategies in clinical and public health settings.

Disease(s): Respiratory infections

Method(s): General respiratory patient care Public health

Tag(s): Clinical

13:15

Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Journalist

Chairs: Raquel Duarte (Porto, Portugal), Chair to be confirmed

12:45 The Global Impact of Vaccination: Insights from 50 Years of Immunization

Speaker to be confirmed

13:00 Innovations in Vaccine Technology for Respiratory Infections

Speaker to be confirmed

How to Increase Uptake? Overcoming Barriers and Building Trust

Speaker to be confirmed

13:30 Discussion and Q&A

Speaker to be confirmed

5B Session 13:45 - 15:15

Symposium: Lung cancer and severe respiratory comorbidities – navigating complex clinical challenges

Aims: 1. Understand the impact of common respiratory comorbidities (COPD, emphysema, ILD) on the management of thoracic malignancies.

- 2. Explore multidisciplinary approaches to tailoring treatment plans based on comorbidity burden.
- 3. Discuss the challenges and strategies for lung cancer diagnosis in patients with severe respiratory comorbidities.
- 4. Learn about the latest advances in treatment modalities, including immunotherapy, target therapy, chemotherapy, radiotherapy and surgery, and their implications in patients with comorbidities.

34

5. Discuss supportive care strategies, including managing complications and improving patient quality of life.

Disease(s): Airway diseases Interstitial lung diseases Thoracic oncology

Method(s): Palliative care Pulmonary function testing Surgery

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Nurse, Physician in Pulmonary Training, Thoracic oncologist,

Thoracic surgeon

Chairs: Maria Joana Pereira Catarata (Porto, Portugal), Elżbieta Magdalena Grabczak (Warszawa, Poland)

13:45 Diagnosing lung cancer in patients with severe respiratory comorbidities – who, when and why? Georgia Hardavella (Athens, Greece)

14:00 COPD and Lung Cancer: navigating treatment challenges in the presence of obstructive lung disease Joanna Chorostowska-Wynimko (Warsaw, Poland)

14:15 Interstitial Lung Disease and Lung Cancer: risks, complications and treatment strategies
Torsten Gerriet Blum (Berlin, Germany)

14:30 Impact of pulmonary hypertension on lung cancer management Mona Lichtblau (Zürich, Switzerland)

14:45 Discussion and Q&A Speaker to be confirmed

5C Session 13:45 - 15:15

Symposium: AI on Air: Global Insights on Utilising Real World Data (RWD)/Real World Evidence (RWE) to Deploy Responsible AI-enabled Respiratory Innovation

Aims: This symposium aims to explore global perspectives on utilizing Real-World Data (RWD) and Real-World Evidence (RWE) to enhance responsible AI-enabled respiratory innovation. By examining exemplary applications of RWD and RWE for respiratory conditions such as lung cancer, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and asthma—from diagnosis to self-management—we can understand the similarities and differences in approaches across various regions. This understanding will foster a collaborative environment that promotes ethical, effective, and innovative solutions to improve the respiratory health.

The objectives are:

1. Promote Global Collaboration: Bring together experts from different regions to share their experiences, methodologies, and outcomes in using RWD and RWE for AI-enabled respiratory innovation.

2. Highlight Regional Opportunities and Challenges: Discuss the opportunities and challenges in the collection, analysis, and the deployment of responsible and effective AI integration at their countries.

3. Understand Country-based Differences: Discuss the similarities and differences in how various regions approach the use of RWD and RWE, and how these differences impact the deployment of AI-enabled respiratory innovation.

Disease(s): Airway diseases Interstitial lung diseases Respiratory infections

Method(s): General respiratory patient care Imaging Public health

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Scientist (basic, translational), Thoracic oncologist, Respiratory therapist, Journalist

Chairs: Io Chi-Yan Hui (Edinburgh (Edinburgh), United Kingdom), Chair to be confirmed

EU Prospective: AI-enabled Real World Data (RWD) in supporting responsible regulatory decisionmaking and health technology assessment (HTA) along the product lifecycle. Speaker to be confirmed

UK Prospective: Utilizing Federated AI with RWD for scalable, safe, robust and fair AI in a healthcare setting
Speaker to be confirmed

LMIC Realities: AI-SaMD Legislation Adoption Challenges and Solutions with RWD throughout the product development lifecycle.

Speaker to be confirmed

14:30 East Asia Realities: From Data to Dollars, the Role of RWD and Reimbursement in AI Deployment. Speaker to be confirmed

35

14:45 Discussion and Q&A Speaker to be confirmed

7A Session 13:45 - 15:15

Symposium: Innovations in Pulmonary Vascular Imaging: From Cutting-Edge Techniques to AI-Driven Insights

Aims: Pulmonary vascular diseases present complex challenges that require advanced imaging techniques for timely and accurate diagnosis. This session focuses on the latest innovations in pulmonary vascular imaging, including CT angiography, MRI, point-of-care ultrasound, and the integration of AI. Participants will also learn about the significant roles of SPECT/VQ and PET imaging in evaluating pulmonary embolism and vascular inflammation. A solid understanding of these imaging modalities is essential for respiratory physicians and allied professionals to enhance diagnostic accuracy, guide clinical management, and improve patient outcomes in conditions like pulmonary embolism and pulmonary hypertension. Each sub talks, will also focus on growing role of AI in the imaging modality being discussed.

Disease(s): Pulmonary vascular diseases Respiratory critical care

Method(s): Imaging Physiology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Patient, Physician in Pulmonary Training, Physiologist, Radiologist

Chairs: Marc Humbert (Le Kremlin-Bicêtre, France), Marion Delcroix (Leuven, Belgium), Athénaïs Boucly (Paris, France)

13:45 CT Angiography Unveiled: The Gold Standard for Pulmonary Vascular Diagnosis Parth Rali (Philadelphia, United States)

14:00 Magnetic Resonance Imaging in Pulmonary Hypertension: A Non-Invasive Game-Changer David Kiely (Sheffield (South Yorkshire), United Kingdom)

14:15 Nuclear Medicine in Focus: The Power of SPECT/VQ and PET Imaging Pierre-Yves Leroux (Brest, France)

Tiene Tves Beream (Bress, Transe)

14:30 Point-of-Care Ultrasound in Pulmonary Embolism: Rapid Diagnostics at Your Fingertips Belinda Rivera-Lebron (Pittsburgh, United States)

14:45 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session 13:45 - 15:15

Symposium: Respiratory health around the globe Congress chairs' session

Aims: Fo the congress chair session we would like to elaborate on the theme of this year 'Respiratory health around the globe' Aims of this session are:

- to raise awareness of the morbidity and mortality due to respiratory diseases worldwide

- to learn about early life determinants of respiratory health and potential preventive measure, with a focus on LMIC
- learn how to reduce mortality from pneumonia, the leading cause of death in children < 5 years of age
- get an insight on how WHO works and how this organization aims to reduce morbidity and mortality of respiratory diseases

- get inspiration from a lawyer fighting climate change

Disease(s): Airway diseases Paediatric respiratory diseases Respiratory infections

Method(s): Epidemiology General respiratory patient care Public health

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Respiratory therapist, Journalist

Chairs: Marielle Pijnenburg (Rotterdam, Netherlands), Lieuwe D.J. Bos (Amsterdam, Netherlands)

Drivers of respiratory health in LMICs: challenges and opportunities

Diane Gray (Cape Town, South Africa)

Pneumonia: a global problem from infancy to the elderly

Catia Cilloniz Campos (Barcelona, Spain)

Global strategies for improving respiratory health: how the WHO can make a difference in respiratory

36

14:15 health?

JOSE LUIS CASTRO (Neuilly sur Seine, France)

14:30 Fighting climate change: what can health care providers learn from lawyers? Maikel van Wissen (Amsterdam, Netherlands)

14:45 Discussion and Q&A Speaker to be confirmed

Auditorium Session 13:45 - 15:15

State of the art session: Airway diseases

Biologics in Airway Diseases: Bridging Immunology and Clinical Breakthroughs

Aims: This symposium aims to provide a deep dive into the evolving role of biologic therapies in the management of airway diseases. Attendees will gain insights into the mechanisms behind biologics, their clinical applications, and future directions in their use in the management of asthma, COPD and their exacerbations. The overarching goal is to equip clinicians and researchers with practical and theoretical knowledge to optimise patient care and make informed decisions regarding the use of biologics in airway disease management.

Disease(s): Airway diseases

Method(s): Cell and molecular biology General respiratory patient care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Nurse, Patient, Scientist (basic, translational)

Chairs: Alexander Mathioudakis (Manchester, United Kingdom), Ildikó Horváth (Budakeszi, Hungary), Chair to be confirmed

13:45 Airway Diseases Immunology for Clinicians in the Biologics Era

Lena Üller (Lund, Sweden)

- 14:00 Biologics in asthma: Current insights and future directions Guy Brusselle (Ghent, Belgium)
- 14:15 Biologics in COPD: Targeting the Right Pathways for the Right Treatments
 Gerard J. Criner (Philadelphia, United States)
- 14:30 Biologics in Airway Disease Exacerbatoins: Time to Replace Systemic Corticosteroids.

 Mona Bafadhel (London, United Kingdom)
- 14:45 Discussion and Q&A Speaker to be confirmed

5A Session 13:45 - 15:15

Journal session: Highlights from JAMA

Bisoprolol for patients with COPD; high-intensity vs low-intensity positive pressure ventilation for acute exacerbations of COPD; high-flow nasal oxygen vs non-invasive ventilation for acute respiratory failure; video laryngoscopy vs direct laryngoscopy for endotracheal intubation in the operating room

Aims: 1. Provide update on effect of Bisoprolol on respiratory exacerbations in patients with COPD at high-risk of exacerbations.

- 2. Provide update on use of high-intensity vs low-intensity positive pressure ventilation for acute exacerbations of COPD.
- 3. Provide update on use of high-flow nasal oxygen vs non-invasive ventilation for acute respiratory failure.

Disease(s): Airway diseases Respiratory critical care

Method(s): Epidemiology General respiratory patient care Respiratory intensive care

Tag(s): Clinical

Target audience : Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory critical care physician, Physician in Pulmonary Training, Respiratory physiotherapist

37

Chairs: Kristin Walter (Chicago, United States)

- 13:45 Introduction
 - Kristin Walter (Chicago, United States)
- 14:00 Effect of Bisoprolol on patients with COPD at high-risk of exacerbations
 - Speaker to be confirmed
- 14:15 High-intensity vs low-intensity positive pressure ventilation for acute exacerbations of COPD
- Speaker to be confirmed
- High-flow nasal oxygen vs non-invasive ventilation for acute respiratory failure
- Israel Silva Maia (Florianópolis (SC), Brazil)
- 14:45 Discussion and Q&A

Speaker to be confirmed

5D Session 13:45 - 15:15

Mini symposium: The lung in a circular health perspective

Aims: We live in a rapidly changing world and the quality of the air we breathe, the food we eat, the water we drink and the pathogens we encounter as well as our lifestyle impact on our health. We live in symbiosis with our microbiome, which represents 90% of our body. Being directly exposed to air, our respiratory tracts are primarily affected by the quality of the air we breathe and for this reason air pollution has been looked as a major cause of respiratory diseases. Nevertheless, there is a growing appreciation that other environmental factors, life habits and exposure to pathogens have a profound impact on respiratory health. The aims of the Mini-Symposium is to provide the tools to the audience to understand how the "exposome" approach has opened new perspectives on this and can provide an integrated and holistic view of the human organism within the world we live in. By participating to this Mini-Symposium, attendants will be able to catch how the interaction between the environment and our airways can shape our health and our immune defenses and how to apply the concept of "One health" in the context of respiratory health. Participants will be able to learn how dynamic host-pathogen interactions drive innate immune activation, especially in early age, which may reveal news strategies to face future viral pandemics. In this respect, a special focus will be on the early stages of life, which are crucial for lung development and respiratory health during the course of life. Finally, participation to this Mini-Symposium will provide attendees with improved awareness on how to turn this knowledge into new clinical practices and actions that may change the course of the history and, by improving the health of our planet, can lead to the improvement of our respiratory health.

Disease(s): Airway diseases Paediatric respiratory diseases Respiratory infections

Method(s): Cell and molecular biology Epidemiology Public health

Tag(s): Congress theme: Respiratory health around the globe

Target audience : Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Pathologist, Patient, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

Chairs: Chiara Cipollina (Palermo (PA), Italy)

SARS-CoV-2 infection: a lesson of "Circular Health" as a vital circular junction between humans and nature.
Speaker to be confirmed

Not just air pollution: The exposome approach reveals the complex interplay between the environment and our respiratory health.
Speaker to be confirmed

14:15 Virus in the air: How host-pathogen interactions shape airways immune responses
Ellen Foxman (New Haven, United States)

14:30 Discussion and Q&A
Speaker to be confirmed

G104/105 Session 14:30 - 16:50

Skills workshop: SW10 SW10 - Practicalities of pulmonary function testing: spirometry, whole-body plethysmography and diffusion

Additional registration is required for this session.

Aims: This skills workshop will help attendees gain the technical expertise needed to perform spirometry, whole body plethysmography and diffusion test according to both best practice and the latest recommendations that are supported by experts in the field; to understand the measurement principles and technical aspects of spirometry, static lung volumes, airway resistance and diffusion capacity of the lungs; and to learn about the standardisation of test performance, reporting and case study interpretation.

Disease(s): Airway diseases Paediatric respiratory diseases

Chairs: Rachel Ong-Salvador (Amsterdam, Netherlands)

14:30 Performing Spirometry Lindsay Zurba (Durban, South Africa)

Standardised static lung volume measurement and airways resistance using whole body plethysmography

Vicky Moore (Coventry, United Kingdom)

14:30 Measurement of the diffusing capacity of the lungs for carbon monoxide using the single-breath method Kevin De Soomer (Edegem, Belgium)

38

14:30 Reporting and interpretation of case studies
Karl Sylvester (Cambridge (Cambridgeshire), United Kingdom)

G106/107 Session 14:30 - 16:50

Skills workshop: SW12 SW12 - Practical Pulmonary Hypertension Additional registration is required for this session.

Aims: 1. Develop a practical approach to investigating and diagnosing PH

- 2. Develop a systematic approach to interpreting radiological investigations
- 3. Understand the 4 main echo views and important features of PH at echocardiography including hands-on experience with PH patients and healthy volunteers
- 4. Understand the pathological changes associated with different forms of PH and appreciate how these translate into clinical phenotypes
- 5. Understand right heart catheterization and be able to incorporate clinical, radiological and haemodynamic features to make the correct diagnosis

Disease(s): Pulmonary vascular diseases

Tag(s): Clinical

Chairs: Esther Nossent (Amsterdam, Netherlands)

- 14:30 Radiological assessment of pulmonary hypertension
 Andy Swift (Sheffield (South Yorkshire), United Kingdom)
- 14:30 Pathological assessment of pulmonary hypertension Speaker to be confirmed
- 14:30 Echocardiography in pulmonary hypertension Athanasios Charalampopoulos (London, United Kingdom)
- 14:30 Clinical assessment of pulmonary hypertension
 Robin Condliffe (Sheffield (South Yorkshire), United Kingdom)

5B Session 15:30 - 17:00

Symposium: Pleural disease: the Global view

Aims: Aims for the audience are to understand the global heterogeneity in diagnosis, treatment, and management of pleural disease, and the gap between current guidelines and what can be provided in low-middle income countries.

Disease(s): Respiratory infections Thoracic oncology

Method(s): Endoscopy and interventional pulmonology Imaging Palliative care

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Nurse, Patient, Physician in Pulmonary Training, Radiologist, Thoracic oncologist, Thoracic surgeon, Respiratory therapist

Chairs: Maria Joana Pereira Catarata (Porto, Portugal), Elżbieta Magdalena Grabczak (Warszawa, Poland)

- 15:30 A World-wide Perspective of Pleural infection: implications on management
 - Maged Hassan (Alexandria, Egypt)
- 15:45 Secondary spontaneous pneumothorax and air-leak: global lessons. Steven Walker (Bristol (Avon), United Kingdom)
- Diagnosis and management of malignant pleural effusions in resource-constrained settings
- 16:00 Coenraad Frederik Nicolaas Koegelenberg (Cape Town, South Africa)
- Cost effective imaging in pleural disease: the real-world application of pleural ultrasound in low-to-middle-income countries
- Radhika Banka (Mumbai (Maharashtra), India)
- 16:30 Discussion and Q&A Speaker to be confirmed

7A Session 15:30 - 17:00

Symposium: A Global Perspective on Pulmonary Hypertension

Aims: To explain the heterogeneous landscape of pulmonary hypertension across the globe. The participant will be able to describe the diverse epidemiology of pulmonary hypertension and the diagnostic and therapeutic challenges in different settings. Furthermore, the symposium will identify how global challenges such as social inequality and climate change affect patients with pulmonary hypertension. Finally, the symposium will compare the opportunities and limitations of conducting research with PH patients in countries with different income levels.

39

Disease(s): Airway diseases Interstitial lung diseases Pulmonary vascular diseases

Method(s): Epidemiology Imaging Transplantation

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist

Chairs: Marc Humbert (Le Kremlin-Bicêtre, France), Marion Delcroix (Leuven, Belgium), Athénaïs Boucly (Paris, France)

15:30 The global epidemiology of pulmonary hypertension. Sandeep Sahay (Houston, United States)

15:45 Diagnosis and treatment of pulmonary hypertension in low, middle and high income countries.

How do social inequality, environmental pollution and climate change affect patients with pulmonary hypertension?

Lucilla Piccari (Barcelona, Spain)

16:15 Interventional and observational clinical trials on pulmonary hypertension across the world. Jason Weatherald (Edmonton, Canada)

16:30 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session 15:30 - 17:00

Year in review: Peadiatric

Aims: To provide an update on four topics in paediatric respiratory medicine, namely, impact of disease modifying therapies on respiratory outcomes in children with neuromuscular disorders, Mycoplasma infections in children; asthma remission in childhood and use of artificial intelligence in pediatric pulmonology practice to highlight the most recent and significant publications and developments related to these topics.

Disease(s): Airway diseases Paediatric respiratory diseases Respiratory infections

Method(s): Epidemiology Imaging Physiology

Tag(s): Clinical

Target audience : Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Physician in Pulmonary Training, Radiologist, Respiratory therapist, Journalist

Chairs: Marielle Pijnenburg (Rotterdam, Netherlands)

Impact of disease modifying therapies on respiratory outcomes in children with neuromuscular

15:30 disorders

Reshma Amin (Toronto (ON), Canada)

Mycoplasma: the new pandemic. Epidemiological considerations and therapy

Patrick M. Meyer Sauteur (Zurich, Switzerland)

16:00 Asthma remission in children: is it achievable? Refiloe Masekela (Durban, South Africa)

How can we use artificial intelligence in clinical practice of pediatric pulmonologists?

Gustavo Nino (Washington, United States)

16:30 Discussion and Q&A Speaker to be confirmed

Auditorium Session 15:30 - 17:00

Clinical cases: Lungs on fire: Airway diseases?

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

40

Disease(s): Airway diseases

Tag(s): Clinical

Chairs: Alexander Mathioudakis (Manchester, United Kingdom), Ildikó Horváth (Budakeszi, Hungary), Chair to be confirmed

Discussants: Arzu Yorgancıoğlu (İzmir, Turkey), Omar S. Usmani (London, United Kingdom)

15:30	Case 1 incl. panel discussion and Q&A Arzu Yorgancıoğlu (İzmir, Turkey)
15:52	Case 2 incl. panel discussion and Q&A Omar S. Usmani (London, United Kingdom)
16:14	Case 3 incl. panel discussion and Q&A Arzu Yorgancıoğlu (İzmir, Turkey)
16:36	Case 4 incl. panel discussion and Q&A Omar S. Usmani (London, United Kingdom)

5C Session 15:30 - 17:00

Mini symposium: Lung Sounds Unplugged : a Global perspective Global challenges in respiratory sound analysis from early respiratory diseases detection to the exacerbation management

Aims: 1) To provide an updated operational classification of lung (and other respiratory) sounds across several physio(patho)logical respiratory conditions

2) To describe technical aspects and applications of lung sound analysis in clinical practice: - early diagnosis (es. ILDs) - early detection of

exacerbations/progression of the disease

3) To introduce telemedicine applications of respiratory sound analysis in the clinical management of adult and paediatric pulmonology in low-resource settings

Disease(s): Airway diseases Interstitial lung diseases Paediatric respiratory diseases Method(s): General respiratory patient care Physiology Pulmonary function testing

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Thoracic oncologist, Thoracic surgeon, Respiratory therapist, Journalist

Chairs: Io Chi-Yan Hui (Edinburgh (Edinburgh), United Kingdom), Chair to be confirmed

- 15:30 Automated detection of respiratory diseases from lung and respiratory sounds
- 15:45 Remote monitoring applications of cough and respiratory sounds analysis Jaclyn Smith (Manchester, United Kingdom)
- 16:00 Acceptability of digital stethoscope technology in a low resource setting Salahuddin Ahmed (Dhaka, Bangladesh)
- 16:15 Discussion and Q&A Speaker to be confirmed

Elicium 1 Session 15:45 - 17:00

Symposium: Early Career Member session

Aims: The Early Career Member (ECM) session aims to bring together all respiratory professionals at their early stages to discuss key aspects for a career development in respiratory medicine. The topics were selected based on the priority topics identified by the ECM Committee. The speakers of the sessions were selected based on their successful involvements with ERS and the evidence of skills tailored to the topic of the session.

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Respiratory therapist

41

Chairs: Thomas Gille (Bobigny, France), Dorina Esendagli (Ankara, Turkey)

- 15:45 Advocacy: influencing the context for change' or 'Advocacy: when change is essentia Speaker to be confirmed
- 16:00 Why women make fewer medical errors than men? Franziska Trudzinski (Heidelberg, Germany)
- 16:15 Mina Gaga Lecture

Get involved with ERS to boost your career! Sara Cuevas Ocaña (Jaen, Spain) 16:30

Discussion and Q&A 16:45 Speaker to be confirmed

26.03.2025

42

G104/105 Session 08:00 - 10:40

Skills workshop: SW13 SW13 - Thoracic ultrasound basic principles Additional registration is required for this session.

Aims: To describe the current use of thoracic ultrasound; to provide participants an opportunity to perform this technique using training models, simulators, volunteers and patients.

Disease(s): Thoracic oncology Interstitial lung diseases

Method(s): General respiratory patient care Imaging

Target audience: Radiologist, Thoracic surgeon, Adult pulmonologist/Clinician, Clinical researcher, Respiratory critical care physician, Physician in Pulmonary Training

Chairs: Christian Borbjerg Laursen (Odense M, Denmark)

08:00	Introduction Christian Borbjerg Laursen (Odense M, Denmark)
08:20	Normal Thoracic Cavity Casper Falster (Odense, Denmark), Jesper Rømhild Davidsen (Odense C, Denmark)
08:20	Pleural effusion and / or pleural thickening Gilles Mangiapan (Creteil, France), Speaker to be confirmed
08:20	Case studies Rob Hallifax (Oxford (Oxfordshire), United Kingdom)
08:20	Guided interventions Søren Helbo Skaarup (Aarhus C, Denmark), Rahul Bhatnagar (Bristol, United Kingdom)

Elicium 2 Session 08:30 - 10:00

Symposium: Real-world challenges in asthma: beyond pharmacotherapy

Aims: This session aims to address the multifaceted challenges faced in asthma management, moving beyond the realm of pharmacotherapy. Asthma is a complex condition influenced by a range of factors, from the diagnostic process to individualized monitoring and environmental influences. The session will explore these aspects by highlighting the diagnostic complexities, understanding the clinical relevance of phenotypes and endotypes, and showcasing innovations in personalized monitoring. Additionally, it will focus on how environmental and lifestyle factors can exacerbate asthma and affect patient outcomes. By integrating these elements, the session seeks to provide a holistic view of asthma management in real-world settings.

Disease(s): Airway diseases Paediatric respiratory diseases

Method(s): Epidemiology General respiratory patient care Public health

Tag(s): Clinical

Target audience : Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

Chairs: Matteo Bonini (Rome, Italy), Bianca Brandon (London, United Kingdom)

08:30	Asthma diagnosis: A complex pathway to clarity Imran Satia (Hamilton, Canada)	
08:45	Physical deconditioning and obesity in asthma. A suitable case for rehabilitation Florence Schleich (Liège, Belgium)	
09:00	Self-management of asthma through patient education and action plans	
09:15	Addressing environmental and lifestyle factors. Arzu Yorgancıoğlu (İzmir, Turkey)	
09:30	Discussion and Q&A Speaker to be confirmed	

Auditorium Session 08:30 - 10:00

43

Endoscopy session: Session 1: Interstital lung disease and lung cancer

Disease(s): Thoracic oncology

Method(s): Endoscopy and interventional pulmonology

Chairs: Felix J.F. Herth (Heidelberg, Germany)

08:30	Case 1: Case introduction (AUMC)		
08:35	Case 1: Cryobiopsy for interstitial lung disease Sara Tomassetti (Florence, Italy), Peter I. Bonta (Amsterdam, Netherlands), Speaker to be confirm	ed	
08:55	Case 1: Concluding remarks from the Chairs Felix J.F. Herth (Heidelberg, Germany)		
09:00	Case 2: Case introduction (AUMC)		
09:05	Case 2: Cone beam navigation bronchoscopy suspected lung cancer Erik H.F.M. van der Heijden (Nijmegen, Netherlands), Speaker to be confirmed		
09:25	Case 2: Concluding remarks from the Chairs Felix J.F. Herth (Heidelberg, Germany)		
09:30	Case 3: Case introduction (AUMC)		
09:35	Case 3: EBUS and EUS-B for the assessment of sarcoidosis Jouke T. Annema (Amsterdam, Netherlands), Konstantina Kontogianni (Heidelberg, Germany)		
09:55	Case 3: Concluding remarks from the Chairs Felix J.F. Herth (Heidelberg, Germany)		
<i>-</i>	σ '	00.20	10.00

5A Session 08:30 - 10:00

State of the art session: Respiratory critical care State of the Art treatment of ARDS

Aims: To describe the State of The Art treatment of ARDS. From pathophysiology to extensive therapeutic options.

Disease(s): Airway diseases Respiratory critical care Respiratory infections

Method(s): General respiratory patient care Physiology Respiratory intensive care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Respiratory therapist

Chairs: Christoph Fisser (Regensburg, Germany), Marieke L. Duiverman (Groningen, Netherlands)

08:30	ARDS phenotyping and outcome Lieuwe D.J. Bos (Amsterdam, Netherlands)
08:45	The role and pathophysiology of severe infections in ARDS Ignacio Martin-Loeches (Dublin, Ireland)
09:00	How to set the ventilator
09:15	Evidence based treatment for severe ARDS: Prone Positioning and ECMO. Christian Karagiannidis (Cologne, Germany)
09:30	Discussion and Q&A Speaker to be confirmed

5C Session 08:30 - 10:00

Mini symposium: Exercise training in severely impaired patients

Aims : After active engagement in the session, participants will be able to:

1. Discuss identifying severely impaired patients with chronic respiratory disease who can benefit from current and emerging forms of exercise training.

44

2. Define the current and emerging concepts and evidence in aerobic exercise training for severely impaired patients with chronic respiratory disease.

3. Analyze the practical application, efficacy, and methods for resistance training in severely impaired patients with chronic respiratory diseases.

Disease(s): Airway diseases

Method(s): Pulmonary rehabilitation

Tag(s): Clinical

09:00

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Physician in Pulmonary Training, Respiratory physiotherapist, Respiratory therapist

Chairs: Anke Lenferink (Oldenzaal, Netherlands), Deniz Inal-Ince (Ankara, Turkey), José Miguel dos Santos Castro Padilha (Porto, Portugal)

08:30 Limitations of exercise training in severely impaired patients: different aspects of difficulties J. Alberto Neder (Kingston (ON), Canada)

Biologic specificities concerning exercise in severely impaired patients

08:45 Practical issues in exercise training in severely impaired patients
Tessa Schneeberger (Schönau am Königssee, Germany)

09:00 Discussion and Q&A Speaker to be confirmed

5C Session 10:15 - 11:4:

Symposium: Holistic, yet personalised self-management in chronic respiratory diseases worldwide

Aims: After active engagement in the session, the participant will be able to:

- identify key elements to personalise self-management in patients with chronic respiratory diseases
- identify key elements for implementation of self-management in chronic respiratory care
- select personalised treatment fitting with treatable traits in chronic respiratory diseases
- match self-management interventions to personal needs and competencies

Disease(s): Airway diseases Respiratory infections

Method(s): Epidemiology General respiratory patient care

Tag(s): Translational, Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

Chairs: Anke Lenferink (Oldenzaal, Netherlands), Deniz Inal-Ince (Ankara, Turkey), José Miguel dos Santos Castro Padilha (Porto, Portugal)

10:15 Personalised self-management for patients with COPD and comorbidities

Hani Syahida Salim (Selangor, Malaysia)

10:30 Implementation of asthma self-management as routine in primary care

Hilary Pinnock (Edinburgh, United Kingdom)

10:45 Challenges in self-management around the globe

Tanja Effing-Tijdhof (Adelaide (SA), Australia)

Future perspectives using new technologies: tailoring of self-management in chronic respiratory

11:00 diseases

Marjolein Brusse-Keizer (Enschede, Netherlands)

11:15 Discussion and Q&A Speaker to be confirmed

Auditorium Session 10:15 - 11:45

45

Endoscopy session: Session 2: Emphysema, lung nodule and pleural disease

Disease(s): Thoracic oncology

Method(s): Endoscopy and interventional pulmonology

Chairs: Daniela Gompelmann (Vienna, Austria), Najib M. Rahman (Oxford, United Kingdom)

10:15 Case 4: Case introduction (AUMC)

Case 4: Bronchoscopic lung volume reduction (BLVR) for emfysema

Dirk-Jan Slebos (Groningen, Netherlands), Stephanie Everaerts (Leuven, Belgium)

10:40 Case 4: Concluding remarks from the Chairs

Daniela Gompelmann (Vienna, Austria), Najib M. Rahman (Oxford, United Kingdom)

Case 5: Case introduction (AUMC)
Case 5: Robotic bronchoscopy for pheripheral lung nodule analysis # Speaker to be confirmed
Case 5: Concluding remarks from the Chairs Daniela Gompelmann (Vienna, Austria), Najib M. Rahman (Oxford, United Kingdom)
Case 6: Case introduction (AUMC)
Case 6:Thoracoscopy in malignant pleural disease Kevin Blyth (Glasgow (Glasgow), United Kingdom), Speaker to be confirmed
Case 6: Concluding remarks from the Chairs Najib M. Rahman (Oxford, United Kingdom), Daniela Gompelmann (Vienna, Austria)
() () () () () () () () () () () () () (

7A Session 10:15 - 11:45

Year in review: Clinical

Global updates on screening and therapeutic intervention development in respiratory diseases

Aims: 1. To evaluate the impact of COPD screening on primary care clinician behavior and patient outcomes

- 2. To appreciate current treatment options and emerging therapeutic approaches for chronic cough
- 3. To review the unmet needs in care for patients with Pulmonary Fibrosis and elaborate on the current methods for delivering patient-centred care
- 4. To consider approaches ensuring that technology is accessible and subject to the same lens as all healthcare interventions

Disease(s): Airway diseases Interstitial lung diseases Respiratory infections

Method(s): Epidemiology Physiology Public health

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

Chairs: Sam Bayat (Grenobe, France), Mathieu Marillier (Echirolles, France)

10:15 COPD screening: pearls and pitfalls

- 10:30 Therapeutic and mechanistic advances in chronic cough Imran Satia (Hamilton, Canada)
 - miran Satia (Tammton, Canada)
- 10:45 ILD: an holistic multidisciplinary approach
 - Katerina Antoniou (Heraklion, Greece)
- Access and Equity in Health Care in the era of digital heath

David Currow (Sydney (NSW), Australia)

11:15 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session 10:15 - 11:45

Journal session: State of the art insights into the prevention, development, and management of the patient with asthma

The Lancet and The Lancet Respiratory Medicine session

Aims: We propose a session based on a Series of Review papers commissioned by The Lancet and The Lancet Respiratory Medicine to be timed to the presentations at the meeting. This forward-looking session will bring together thought leaders in the field to provide an overview of recent research advances related to asthma for specialist and non-specialist delegates. We would aim to provide new insights into the genetics, prevention, and risk factors of the disease; review advances as a result of the use of monoclonal antibody therapeutics; and assess clinical versus biological complete remission in adult patients with moderate-to-severe asthma. We also aim to have a presentation of a late-breaker research article on asthma. The session will therefore comprehensively address areas of debate within the asthma community focused on genetics, prevention, management, and remission as well as featuring impactful clinical research of relevance for respiratory health around the globe.

46

Disease(s): Airway diseases

Method(s): General respiratory patient care Public health Pulmonary function testing

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Physician in

Pulmonary Training, Scientist (basic, translational)

Chairs: Matteo Bonini (Rome, Italy), Bianca Brandon (London, United Kingdom)

10:15 Genetics and risk factors: Improving our understanding of asthma prevention

Guy Brusselle (Ghent, Belgium)

10:30 Precision medicine and the use of monoclonals in the management of asthma

Elliot Israel (Boston, United States)

10:45 Clinical remission in adults with moderate to severe asthma

Celeste Michala Porsbjerg (Copenhagen, Denmark)

11:00 Late-breaker research article on asthma (TBC)

Speaker to be confirmed

11:15 Discussion and Q&A Speaker to be confirmed

5A Session 10:15 - 11:45

Clinical cases: Lungs on fire: Respiratory critical care / Sleep and Breathing disorders

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

Disease(s): Respiratory critical care Sleep and breathing disorders

Tag(s): Clinical

Chairs: Christoph Fisser (Regensburg, Germany), Marieke L. Duiverman (Groningen, Netherlands)

Discussants: Claudia Crimi (Catania (CT), Italy), Patrick Murphy (Oxted (Surrey), United Kingdom)

10:15 Case 1 incl. panel discussion and Q&A

Claudia Crimi (Catania (CT), Italy)

10:37 Case 2 incl. panel discussion and Q&A

Patrick Murphy (Oxted (Surrey), United Kingdom)

10:59 Case 3 incl. panel discussion and Q&A

Claudia Crimi (Catania (CT), Italy)

11:21 Case 4 incl. panel discussion and Q&A

Patrick Murphy (Oxted (Surrey), United Kingdom)

G104/105 Session 11:00 - 13:40

Skills workshop: SW14 SW14 - Thoracic ultrasound basic principles Additional registration is required for this session.

Aims: To describe the current use of thoracic ultrasound; to provide participants an opportunity to perform this technique using training models, simulators, volunteers and patients.

47

Disease(s): Thoracic oncology Interstitial lung diseases

Chairs: Rahul Bhatnagar (Bristol, United Kingdom)

11:00 Introduction

Rahul Bhatnagar (Bristol, United Kingdom)

11:20 Normal Thoracic Cavity

Morten Bendixen (Odense C, Denmark), Silvia Mongodi (Pavia, Italy)

Pleural effusion and / or pleural thickening

Giovanni Volpicelli (Torino (TO), Italy), Speaker to be confirmed

11:20 Case studies

Radhika Banka (Mumbai (Maharashtra), India)

11:20 Guided interventions

Dinesh Addala (Oxford, United Kingdom), Gilles Mangiapan (Creteil, France)

Elicium 1 Session 12:45 - 13:45

Joint session: Inhaler technique, training and technology: making a difference for our patients across the world

Aims: Aim of the above session is to update fellow physicians and health personal on the challenges on choosing and using the proper inhaler for the proper patient, globally and how technology can support us on this.

Disease(s): Airway diseases

Method(s): General respiratory patient care Public health

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Journalist

Chairs: Frans H.C. De Jongh (Enschede, Netherlands), Monbi Stefanova Chakma (London, United Kingdom)

12:45 Choosing the right inhaler and implementing improved inhaler technique in the clinic.

Omar S. Usmani (London, United Kingdom)

13:00 Digital technology to improve inhaler engagement and use

Amy Hai Yan Chan (Auckland, New Zealand)

Global perspectives in inhaler therapy - education, innovation, access and the environment

Job F.M. van Boven (Groningen, Netherlands)

13:30 Discussion and Q&A Speaker to be confirmed

5B Session 13:45 - 15:15

Symposium: Global burden of neonatal and infants' respiratory diseases

Aims: After this symposium, participants will have an overview of the epidemiology, risk factors, disparities and impact of neonatal and infants' respiratory diseases at the global level. The symposium will present the challenges in reducing the global health of respiratory care and equitable access to adequate care for lung diseases in neonates and young children. The symposium will bring together key opinion leaders, researchers, and healthcare professionals to discuss the opportunities of novel technologies and global health strategies to close the gap in outcomes and access to care for neonatal and infants' espiratory diseases across the globe.

48

Disease(s): Paediatric respiratory diseases

Method(s): Epidemiology Public health Respiratory intensive care

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Clinical researcher, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Physician in Pulmonary Training, Respiratory therapist, Journalist

Chairs: Emanuela Zannin (Monza (MB), Italy), Susanne Vijverberg (Amsterdam, Netherlands)

13:45 Global burden of neonatal respiratory distress

Speaker to be confirmed

14:00 Global burden of neonatal and infant respiratory infections

Refiloe Masekela (Durban, South Africa)

14:15 Equity-based preparedness and response actions to paediatric respiratory infections

Speaker to be confirmed

14:30 Equitable access to respiratory support and oxygen therapy devices

Speaker to be confirmed

Discussion and Q&A

Speaker to be confirmed

5D Session 13:45 - 15:15

Symposium: New markers in obstructive sleep apnoea - do they reflect the burden of disease in children and adults?

Aims: To demonstrate the relationship between polysomnographic measures and cardiovascular or neurocognitive outcomes in adults and children with OSA and to adress therapeutic effects on these consuequences (two talks on adults, two talks on children, one about diagnostic markers each and one about therapeutic effects each).

- Identify predictors of favorable response to CPAP in relation to cardiovascular morbidity

- To compare the efficacy of CPAP for primary prevention with secondary prevention of cardiovascular disease associated with OSA.
- To explain why caregiver-reported symptoms and OSA-related morbidity should likely take precedence over AHI when making treatment recommendations for children with snoring.
- Describe the clinical challenges of using the AHI as a measure for defining residual OSA after adenotonsillectomy in children with snoring.

Disease(s): Paediatric respiratory diseases Sleep and breathing disorders

Method(s): General respiratory patient care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Physiologist

Chairs: Manuel Sanchez De La Torre (Toledo, Spain)

New diagnostic markers for OSA reflecting disease burden in adults

Raphael Heinzer (Lausanne, Switzerland)

- 14:00 Primary and secondary cardiovascular prevention in the context of OSA: What we know, what we need Esther Irene Schwarz (Zürich, Switzerland)
- 14:15 How to capture disease burden in children with OSA Refika Hamutcu Ersu (Ottawa, Canada)
- Apnea-hypopnea index in children with snoring does not define phenotypes responsive to adenotonsillectomy

Athanasios G. Kaditis (Athens, Greece)

14:45 Discussion and Q&A Speaker to be confirmed

5C Session 13:45 - 15:15

Symposium: Global respiratory health and Tobacco: Challenges, impacts, and pathways to a smoke-free future

Aims: 1. To assess the global burden of respiratory diseases linked to tobacco use

- 2. To evaluate the impact of emerging tobacco products
- 3. To address inequities in respiratory health and tobacco control
- 4. To contribute best practices for tobacco control policies

Disease(s): Airway diseases Paediatric respiratory diseases Respiratory infections

Method(s): Epidemiology General respiratory patient care Public health

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Thoracic oncologist, Thoracic surgeon, Respiratory therapist, Journalist

49

Chairs: Ulrike Gehring (Utrecht, Netherlands), Filippos T. Filippidis (Rickmansworth, United Kingdom)

13:45 Challenges in implementing cessation policies to address the tobacco epidemic

María Felicia Montero Arias (San José, Costa Rica)

Designing environment smoke free cities for optimal respiratory health: Innovations, policies, and sustainable practices

Isabella Annesi Maesano (Montpellier, France)

Addressing inequalities among smokers: Bridging the gaps in health, access, and outcomes

Stamatoula Tsikrika (Athens, Greece)

Addressing the impact of secondhand smoking on asthmatic and COPD patient

Chin Kook Rhee (Seoul, Republic of Korea)

14:45 Discussion and Q&A Speaker to be confirmed

Elicium 2 Session 13:45 - 15:15

Symposium: "ILD around the world" Cultural and regional differences

Aims: Objectives for the ILD around the world symposium will include but not limited to:

- 1. Education and Awareness: Increase knowledge and awareness among healthcare professionals about the diagnosis, management, impact of ILD, and show the differences in our continents
- 2. Multidisciplinary Collaboration: Foster collaboration among pulmonologists, radiologists, pathologists, researchers, and other specialists around the world, to share insights and develop more effective treatment protocols.
- 3. Patient-Centered Approaches: Discuss the reality and differences in our continents about patient care strategies that focus on improving quality of life, early diagnosis, and personalized treatment plans based on individual disease progression and characteristics.
- 4. Best Practices in Management: share clinical guidelines, case studies, and best practices for the management of ILD.

Disease(s): Interstitial lung diseases Respiratory infections

Method(s): Epidemiology General respiratory patient care Palliative care

Tag(s): Clinical, Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher

Chairs: Marlies S. Wijsenbeek (Rotterdam, Netherlands), Cormac McCarthy (Dublin 4, Ireland), Laura Fabbri (London, United Kingdom)

- 13:45 Differences in prevalence and treatment of HP worldwide Carlos Alberto De Castro Pereira (São Paulo (SP), Brazil)
- 14:00 Cultural differences in palliative care for ILD
- Speaker to be confirmed
- 14:15 Is there a regional difference in acute exacerbations of fibrosing ILDs? Yasuhiro Kondoh (Seto (Aichi), Japan)
- 14:30 Racial and ethnic disparities in therapy of interstitial lung diseases could be? Ayodeji Adegunsoye (Chicago, United States)
- 14:45 Discussion and Q&A Speaker to be confirmed

7A Session 13:45 - 15:15

Respiratory medicine meets other disciplines: Right ventricular phenotypes in heart and lung

Aims: Discuss RV physiology and pathophysiology in different clinical circumstances, from chronic COPD or ILD to pulmonary hypertension associated with systemic diseases

Provide an overview of right heart function in the peripartum period of a patient with pulmonary hypertension

Disease(s): Pulmonary vascular diseases Respiratory critical care

Method(s): General respiratory patient care Physiology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Respiratory critical care physician, Physician in Pulmonary Training

Chairs: George Giannakoulas (Thessaloniki, Greece), Harm Jan Bogaard (Amsterdam, Netherlands)

- 13:45 Cor Pulmonale revisited
 - Gabor Kovacs (Graz, Austria)
- 14:00 Right ventricular phenotypes in left heart disease
 - Stephan Rosenkranz (Köln, Germany)
- 14:15 Tricuspid repair in the pressure overloaded right heart. No, no, no...or perhaps sometimes?
- 14:30 Right ventricular function in the peri-partum period
 - Da-Hee Park (Hannover, Germany)
- 14:45 Discussion and Q&A

Speaker to be confirmed

50 26.03.2025

Auditorium Session 13:45 - 15:15

State of the art session: Respiratory infections

The importance of infection prevention and control to prevent transmission of respiratory infections

Aims: To outline how timely interventions like isolation of symptomatic patients, proper use of PPE, and environmental controls can significantly reduce transmission of mycobacterial and viral respiratory infections - To clarify the lack of appropriate biomarkers for determining infectiousness for mycobacterial and viral respiratory infections - To discuss the importance of controlling the increasing drug-resistant pathogens like multidrug-resistant (MDR) bacteria and drug-resistant tuberculosis (DR-TB), especially in relation to the rising threat of antimicrobial resistance (AMR) in respiratory infections

Disease(s): Paediatric respiratory diseases Respiratory critical care Respiratory infections

Method(s): General respiratory patient care Public health

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

Chairs: Onno Akkerman (Groningen, Netherlands), Markus Fally (Copenhagen, Denmark), Olha Konstantynovska (Kharkiv, Ukraine)

Facing the challenges of curbing the transmission of tuberculosis

Giovanni Battista Migliori (Varese (VA), Italy)

- 14:00 The impact of non-tuberculous mycobacteria among patients with underlying respiratory diseases Mateja Jankovic Makek (Zagreb, Croatia)
- 14:15 Viral point of care testing, prevention and patient cohorting Clarke Tristan (Southampton, United Kingdom)
- 14:30 Antimicrobial Resistance in Respiratory Infections: Challenges Speaker to be confirmed
- 14:45 Discussion and Q&A Speaker to be confirmed

5A Session 13:45 - 15:15

Clinical cases: Clinical challenges beyond guidelines

Aims : To describe the controversial aspects of the current guidelines for acute respiratory distress syndrome, mesothelioma, tuberculosis short regimens and resectability for N2 non small cell lung cancer and selection criteria for sequence of treatment allocation; to propose evidence-based substitute management recommendations for clinicians; to identify areas of concern; to highlight the need for further research; to explain the limitations of the guidelines in order to put them in some prospective and clinical practice.

Chairs: Torsten Gerriet Blum (Berlin, Germany)

- 13:45 Limitations of acute respiratory distress syndrome guidelines, incl. Q&A Ana Cysneiros (Lisboa, Portugal)
- 14:07 Weak points of modern guidelines for MPM and future perspective, incl. Q&A Nuria M. Novoa (Majadahonda, Spain)
- 14:29 Overcoming Barriers to Access and Implementing TB Short Regimens, incl. Q&A Lorenzo Guglielmetti (Paris, France)
- Standardized definition of resectability for N2 non small cell lung cancer and selection criteria for sequence of treatment allocation. Variability across guidelines, incl. Q&A

 Alessandro Brunelli (Leeds (West Yorkshire), United Kingdom)

Alessandro Brunelli (Leeds (West Yorkshire), United Kingdom)

14:30 - 17:10

Skills workshop: SW15 SW15 - Thoracic ultrasound basic principles Additional registration is required for this session.

Aims: To describe the current use of thoracic ultrasound; to provide participants an opportunity to perform this technique using training models, simulators, volunteers and patients.

51

Session

Disease(s): Thoracic oncology Interstitial lung diseases
Chairs: Najib M. Rahman (Oxford, United Kingdom)

The state of the s

G104/105

14:30

Najib M. Rahman (Oxford, United Kingdom)

14:50 Normal Thoracic Cavity
Giovanni Volpicelli (Torino (TO), Italy), Morten Bendixen (Odense C, Denmark)

14:50 Pleural effusion and / or pleural thickening
Konstantina Kontogianni (Heidelberg, Germany), Valentina Pinelli (MASSA-CARRARA, Italy)

14:50 Case studies
Poppy Denniston (London, United Kingdom)

14:50 Guided interventions
Søren Helbo Skaarup (Aarhus C, Denmark), Beenish Iqbal (Oxford, United Kingdom)

5B Session 15:30 - 17:00

Symposium: Rare respiratory diseases in children: from misknowledge to personalised medicine

Aims: During this symposium, and thanks to concrete examples in groups of rare lung diseases, the audience will understand how advances in diagnostic and predictive technologies can improve patient care and lead to personalized treatments. This symposium will also present how proof of concepts in monogenic rare lung diseases paves the way for treating other resembling diseases, especially in the field of paediatric interstitial and inflammatory lung diseases. Finally, the audience will improve their knowledge about paediatric lung transplantation by getting an update in the indications, feasibility and prognosis of this procedure in children. Altogether, these advances in paediatric rare lung diseases fit to the one of the themes of the 2025 congress, i.e. "Global burden of disease from infancy to the elderly" for three reasons. First, part of the discoveries led to applications in the field of adult interstitial lung diseases as for the use of jak-inhibitors and methionine. Second, research in the field of congenital pulmonary malformations improved the predicted risk of subsequent cancer in this group of diseases. Finally, by presenting the latest results in paediatric lung transplantation, the audience will be aware that children with previously early lethal rare diseases are now surviving.

Disease(s): Interstitial lung diseases Paediatric respiratory diseases Thoracic oncology

Method(s): Cell and molecular biology General respiratory patient care

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Paediatrician, Patient, Scientist (basic, translational), Thoracic oncologist

Chairs: Emanuela Zannin (Monza (MB), Italy), Susanne Vijverberg (Amsterdam, Netherlands)

Methionine supplementation in pulmonary alveolar proteinosis related to MARS1 mutations: from 15:30 bench side to personalised low-cost treatment Alice Hadchouel-Duvergé (Paris, France) Jak-inhibitors: from the evidenced based use in monogenic auto-inflammatory diseases to the successful 15:45 treatment of connective tissue diseases Stefano Volpi (Genova, Italy) Paediatric lung transplantation: update in the indications, feasibility and prognosis in 2024 16:00 Nicolaus Schwerk (Hannover, Germany) Growing with chILD: towards a specific transition program for a better care 16:15 Effrosyni D. Manali (Athens, Greece) Discussion and O&A 16:30 Speaker to be confirmed

Elicium 2 Session 15:30 - 17:00

52

Symposium: Global disparities in LAM: An example of how ERNs and Technology can help

Aims: The aim of this session is highlight the challenges in delivery of care to rare lung diseases worldwide with lymphangioleiomyomatosis (LAM) as a paradigm of both the challenges and possible successes that can be achieved. LAM is a rare metastatic neoplasm that result in diffuse cystic lung destruction nd multisystem involvement. It primarily presents in women of childbearing age and is driven by female sex hormones. This unique element leads to significant disparities in care across different countries and regions and thus standardising care and educating the broad pulmonary community is of paramount importance. This session will identify the challenges in standardizing care in such a rare disease, contrasting the difficulties in Europe, USA, South America and beyond. The symposium aims to describe how effective patient involvement and PAGs (Patient Advisory Groups) can be in improving care and research in these diseases. It also will identify the benefit of ERNs (European Reference Networks) and how they operate to improve clinical care. The symposium will also address how modern technologies, both clinical and translational, are being used to inform diagnostic ability and improve delivery of care and therapy. The use of AI in imaging and pathology together with the use of home monitoring and machine learning are employed to better predict outcomes and thus harnessing these technologies to better understand this rare disease that is otherwise hard to study globally. The aims are to 1. Understand the role of patient involvement in driving improvements in care and knowledge of LAM 2. Be able to understand the current state of the art in diagnostics of LAM and how new techniques and technology has improved this 3. Differentiate between different countries' care for LAM and how unified approaches can better help all stakeholders 4. Identify the utility of new methods to predict prognosis and determine therapeutic benefit and response in LAM.

Disease(s): Airway diseases Interstitial lung diseases Respiratory critical care

Method(s): Cell and molecular biology Epidemiology Imaging

Tag(s): Congress theme: Respiratory health around the globe

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Nurse, Respiratory critical care physician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Scientist (basic, translational), Thoracic surgeon, Respiratory therapist

Chairs: Marlies S. Wijsenbeek (Rotterdam, Netherlands), Cormac McCarthy (Dublin 4, Ireland), Laura Fabbri (London, United Kingdom)

15:30	The Role of Patient Involvement in Improving Care in LAM Anna Svenningsson (Stockholm, Sweden)
15:45	Global differences in LAM care: challenges and opportunities Bruno Guedes Baldi (São Paulo (SP), Brazil)
16:00	European Reference Networks, Registries and Biobanks: Key to Advancing Care in LAM Marta Garcia Moyano (Barakaldo, Spain)
16:15	Developing novel molecular diagnostic and disease monitoring strategies in LAM Nishant Gupta (Cincinnati, United States)
16:30	Discussion and Q&A Speaker to be confirmed

Auditorium Session 15:30 - 17:00

Clinical cases: Lungs on fire: Respiratory infections?

Aims: to present real-life clinical cases as part of an interactive session. Cases vary in difficulty and may require differential diagnosis. This session is led by two discussants who will present cases submitted by respiratory health professionals to a panel of experts and will drive the discussion in a step-by-step approach, encouraging dialogue and reflection among the panel, who have no prior knowledge of these cases. As the cases are discussed, the discussants will invite the audience to participate in determining which diagnostic and therapeutic options would be best for these patients.

Disease(s): Respiratory infections

Tag(s): Clinical

Chairs: Onno Akkerman (Groningen, Netherlands), Markus Fally (Copenhagen, Denmark), Olha Konstantynovska (Kharkiv, Ukraine)

53

Discussants: Thomas Wilkinson (Southampton (Hampshire), United Kingdom)

15:30 Case 1 incl. panel discussion and Q&A

15:52 Case 2 incl. panel discussion and Q&A
Thomas Wilkinson (Southampton (Hampshire), United Kingdom)

16:14 Case 3 incl. panel discussion and Q&A

16:36 Case 4 incl. panel discussion and Q&A
Thomas Wilkinson (Southampton (Hampshire), United Kingdom)

5D Session 15:30 - 17:00

Mini symposium: Sex differences in sleep-disordered breathing - How does it influence diagnostics and treatment recommendations?

Aims: The aim of this symposium is to highlight the epidemiological and pathophysiological differences between the sexes in sleep-disordered breathing and chronic respiratory failure and to critically discuss how these affect symptoms and treatment outcomes. While sex differences in obstructive sleep apnoea are currently a focus of interest, little is known about sex differences in central sleep apnoea syndromes and obesity-related respiratory failure. The current state of knowledge, and in particular the gaps in knowledge, will be identified to determine future research priorities in this area.

Disease(s): Respiratory critical care | Sleep and breathing disorders

Method(s): Epidemiology General respiratory patient care Physiology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Respiratory therapist

Chairs: Manuel Sanchez De La Torre (Toledo, Spain)

Speaker to be confirmed

15:30 Obstructive sleep apnoea in females – still strangers in the night?

Sophia E. Schiza (Heraklion, Greece)

15:45 Sex differences in obesity-related respiratory failure
Maria Rosaria Bonsignore (Palermo, Italy)

16:00 Central sleep apnoea syndromes – only a male problem?

Jean-Louis Pépin (Grenoble, France)

Discussion and Q&A

Southeat of the state

Elicium 1 Session 15:45 - 17:00

Science slam: Science slam

Aims: Five scientists will present their research in an entertaining way for a non-specialist audience. The audience will elect, by means of electronic voting, the 2025 Science Slam winner.

Target audience: Adult pulmonologist/Clinician, General practitioner, Paediatrician, Nurse, Medical Technical Assistant, Patient, Physician in Pulmonary Training, Clinical researcher, Journalist, Medical Student, Physiologist, Radiologist, Thoracic surgeon, Respiratory physiotherapist, Respiratory critical care physician, Scientist (basic, translational), Respiratory therapist, Pathologist, Thoracic oncologist

Chairs: Sara Cuevas Ocaña (Jaen, Spain), Jannik Ruwisch (Hannover, Germany), Thomas Gille (Bobigny, France)

15:45 Sara Cuevas Ocaña (Jaen, Spain), Thomas Gille (Bobigny, France), Jannik Ruwisch (Hannover, Germany)

15:50 Presenter 1

16:02 Presenter 2

16:14 Presenter 3

16:26 Presenter 4

16:38 Presenter 5

Vote, presentation and interview of the winner Sara Cuevas Ocaña (Jaen, Spain), Thomas Gille (Bobigny, France), Jannik Ruwisch (Hannover, Germany)

5C Session 17:15 - 18:45

54

Assembly members' meeting: Assembly 1 Members meeting: Respiratory clinical care and physiology

Chairs: Ioannis Vogiatzis (Blyth, United Kingdom), Guido Vagheggini (Volterra (PI), Italy), Sam Bayat (Grenobe, France)

17:15 Assembly members meeting: presentation, discussion and Q&A Ioannis Vogiatzis (Blyth, United Kingdom)

3A Session 17:15 - 18:45

Assembly members' meeting: Assembly 2 Members meeting: Respiratory intensive care

Chairs: Christian Karagiannidis (Cologne, Germany), João Carlos Winck (Vila Nova de Gaia, Portugal), Luk Ping Lam (Hong Kong, Hong Kong)

17:15 Assembly members meeting: presentation, discussion and Q&A Christian Karagiannidis (Cologne, Germany)

Elicium 1 Session 17:15 - 18:45

Assembly members' meeting: Assembly 3 Members meeting: Basic and translational sciences

Chairs: H. Irene Heijink (Groningen, Netherlands), Niki L. Reynaert (Maastricht, Netherlands), Arnaud Mailleux (Paris, France)

17:15 Assembly members meeting: presentation, discussion and Q&A H. Irene Heijink (Groningen, Netherlands)

5D Session 17:15 - 18:45

Assembly members' meeting: Assembly 4 Members meeting: Sleep disordered breathing Chairs: Sophia E. Schiza (Heraklion, Greece), Esther Irene Schwarz (Zürich, Switzerland)

17:15 Assembly members meeting: presentation, discussion and Q&A Sophia E. Schiza (Heraklion, Greece)

5A Session 17:15 - 18:45

Assembly members' meeting: Assembly 5 Members meeting: Airway diseases, asthma, COPD and chronic cough

Chairs: Apostolos Bossios (Stockholm, Sweden), Florence Schleich (Liège, Belgium)

17:15 Assembly members meeting: presentation, discussion and Q&A Apostolos Bossios (Stockholm, Sweden)

3B Session 17:15 - 18:45

Assembly members' meeting: Assembly 6 Members meeting: Epidemiology and environment Chairs: Ane Johannessen (Bergen, Norway), Rafael E. de la Hoz (New York, United States)

17:15 Assembly members meeting: presentation, discussion and Q&A Ane Johannessen (Bergen, Norway)

5B Session 17:15 - 18:45

Assembly members' meeting: Assembly 7 Members meeting: Paediatrics

Chairs: Alexander Möller (Zürich, Switzerland), Refika Hamutcu Ersu (Ottawa, Canada)

17:15 Assembly members meeting: presentation, discussion and Q&A Alexander Möller (Zürich, Switzerland)

E102 Session 17:15 - 18:45

Assembly members' meeting: Assembly 8 Members meeting: Thoracic surgery and transplantation Chairs: Federica Meloni (Pavia (PV), Italy), marcello migliore (Catania, Italy), René Hage (Zürich, Switzerland)

17:15 Assembly members meeting: presentation, discussion and Q&A Federica Meloni (Pavia (PV), Italy)

E103/104 Session 17:15 - 18:45

55

Assembly members' meeting: Assembly 9 Members meeting: Allied respiratory professionals

Chairs: Jellien Makonga-Braaksma (Woudenberg, Netherlands), Chris Burtin (Diepenbeek, Belgium)

17:15 Assembly members meeting: presentation, discussion and Q&A Jellien Makonga-Braaksma (Woudenberg, Netherlands)

Auditorium Session 17:15 - 18:45

Assembly members' meeting: Assembly 10 Members meeting: Respiratory infections

Chairs: Raquel Duarte (Porto, Portugal), Onno Akkerman (Groningen, Netherlands)

17:15 Assembly members meeting: presentation, discussion and Q&A Raquel Duarte (Porto, Portugal)

Forum Session 17:15 - 18:4:

Assembly members' meeting: Assembly 11 Members meeting: Thoracic oncology

Chairs: Najib M. Rahman (Oxford, United Kingdom), Georgia Hardavella (Athens, Greece)

17:15 Assembly members meeting: presentation, discussion and Q&A Najib M. Rahman (Oxford, United Kingdom)

Elicium 2 Session 17:15 - 18:45

Assembly members' meeting: Assembly 12 Members meeting: Interstitial lung diseases

Chairs: Michael Kreuter (Mainz, Germany), Marlies S. Wijsenbeek (Rotterdam, Netherlands)

17:15 Assembly members meeting: presentation, discussion and Q&A Michael Kreuter (Mainz, Germany)

7A Session 17:15 - 18:45

Assembly members' meeting: Assembly 13 Members meeting: Pulmonary vascular diseases

Chairs: Olivier Sitbon (Le Kremlin-Bicêtre, France), Harm Jan Bogaard (Amsterdam, Netherlands)

Assembly members meeting: presentation, discussion and Q&A Olivier Sitbon (Le Kremlin-Bicêtre, France)

Amtrium Session 17:15 - 18:45

56

Assembly members' meeting: Assembly 14 Members meeting: Clinical techniques, imaging and endoscopy

Chairs: Walter De Wever (Leuven, Belgium), Elżbieta Magdalena Grabczak (Warszawa, Poland), Mohammed Munavvar (Preston (Lancashire), United Kingdom), Konstantina Kontogianni (Heidelberg, Germany)

Assembly members meeting: presentation, discussion and Q&A Walter De Wever (Leuven, Belgium)

INDUSTRY SESSIONS

57 26.03.2025

E102	Session	10:30 - 11:15
Organised by ResMed		
10:30		
10:48		
11:06		
11:24		
E103/104	Session	10:30 - 11:15
Organised by Philips		
10:30		
10:48		
11:06		
11:24		
E102	Session	14:00 - 14:45
Organised by FUJIFILM		
14:00		
14:18		
14:36		
14:54		
E103/104	Session	14:00 - 14:45
Organised by GANSHORN Medizin Electronic GmbH		
14:00		
14:18		
14:36		
14:54		
E102	Session	15:30 - 16:15
Organised by FUJIFILM		
15:30		
15:48		
16:06		
16:24		
E103/104	Session	15:30 - 16:15
Organised by INOGEN		
15:30		
15:48		
15:48 16:06		

58

E103/104	Session	08:00 - 08:45
Organised by Aerogen		
08:00		
08:18		
08:36		
08:54		
E102	Session	08:00 - 08:45
Organised by Vitalograph		
08:00		
08:18		
08:36		
08:54		
E103/104	Session	10:30 - 11:15
Organised by FUJIFILM		
10:30		
10:48		
11:06		
11:24		
E102	Session	10:30 - 11:15
Organised by ResMed	2.22222	2000 22120
10:30		
10:48		
11:06		
11:24		
E103/104	Session	14:00 - 14:45
Organised by Philips	2 2222	2 11 0 0 2 11 10
14:00		
14:18		
14:36		
14:54		
E102	Session	14:00 - 14:45
Organised by Physio Assist		11.00 11.13
14:00		
14:00		

59

		MONDAY 29 SEPTEMBER, 2025
E103/104	Session	15:30 - 16:15
Organised by FUJIFILM		
15:30		
15:48		
16:06		_
16:24		
E102	Session	15:30 - 16:15
Organised by Fisher & Paykel Healthcare		
15:30		
15:48		_
16:06		
16:24		

ERS Congress 2025

60 26.03.2025

INDUSTRY SESSIONS

E103/104	Session	08:00 - 08:45
Organised by Löwenstein Medical Se & Co. Kg		
08:00		
08:18		
08:36		
08:54		
E102	Session	10:30 - 11:15
Organised by Fisher & Paykel Healthcare		
10:30		
10:48		
11:06		
11:24		
E103/104	Session	10:30 - 11:15
Organised by JAEGGER MEDICAL		
10:30		
10:48		
11:06		
11:24		
E102	Session	14:00 - 14:45
Organised by Air Liquide Healthcare		
14:00		
14:18		
14:36		
14:54		
E103/104	Session	14:00 - 14:45
Organised by BMC Medical Co.Ltd.		
14:00		
14:18		
14:36		
14:54		

61

CHAIR AND COORDINATOR INDEX

Name, Session number

	GILLE T.	ÖCAL N.
A		-
AKKERMAN O.	GLOECKL R.	ONG-SALVADOR R.
ANDREJAK C.	GOMPELMANN D.	<u>P</u>
ANNEMA J.	GOUTAKI M.	PADILHA J.
ANTONIOU K.	GRABCZAK E.	PAPADOPOULOU E.
<u>B</u>	GUIGNABERT C.	PATEL D.
BANKA R.	<u>H</u>	PEREIRA CATARATA M.
BARRECHEGUREN FERNANDEZ M.	HADCHOUEL- DUVERGÉ A.	PERGER E.
BAYAT S.	HAGE R.	PICIUCCHI S.
BEECH A.	HAMUTCU ERSU R.	PIETERSEN P.
BHATNAGAR R.	HARDAVELLA G.	PIJNENBURG M.
BLANC F.	HEIJINK H.	POLVERINO E.
BLUM T.	HERTH F.	POLVERINO F.
BOGAARD H.	HEUVELMANS M.	PRAT AYMERICH C.
BONINI M.	HORVÁTH I.	PREMUDA C.
BOOTS A.	HUI I.	R
BOS L.	HULL J.	RAHMAN N.
BOSSIOS A.	HUMBERT M.	RAMSEY K.
BOUCLY A.	I	REYNAERT N.
BOUTOU A.	INAL-INCE D.	ROCHE N.
BRANDON B.	IQBAL B.	RUWISCH J.
BRAUNSTAHL G.	J	RYAN S.
BURTIN C.	JARA-PALOMARES L.	S
C	JOHANNESSEN A.	SANCHEZ DE LA
CATALDO D.	K	TORRE M.
CHALMERS J.	KAPELLOS T.	SCHIZA S.
CHARPIDOU A.	KARAGIANNIDIS C.	SCHLEICH F.
CHAUDHURI N.	KONGE L.	SCHWARZ E.
CHOROSTOWSKA-	KONSTANTYNOVSKA	SELLARES TORRES J.
WYNIMKO J.	0.	SHTEINBERG M.
CILLONIZ CAMPOS C.	KONTOGIANNI K.	SICILIANO M.
CIPOLLINA C.	KREUTER M.	SITBON O.
CONDLIFFE R.	L	STEFANOVA
CRIMI C.	LAM L.	CHAKMA M.
CROMBAG L.	LAURSEN C.	STRAMBU I.
CUEVAS OCAÑA S.	LAVENEZIANA P.	STRINGER W.
D	LEHMANN M.	V
DAINES L.	LENFERINK A.	VAGHEGGINI G.
DANDANELL JUUL A.	LORENT N.	VAN GEFFEN W.
DE ALMEIDA	M	VIJVERBERG S.
VICENTE FERREIRA C.	MAILLEUX A.	VILLAR ALVAREZ F.
DE JONGH F.	MAITLAND-VAN DER	VOGIATZIS I.
DE LA HOZ R.	ZEE A.	W
DE WEVER W.	MAKONGA- BRAAKSMA J.	WALTER K.
DELCROIX M.	MARILLIER M.	WIJSENBEEK M.
DOST A.	MARQUES A.	WINCK J.
DUARTE R.	MASKELL N.	WUYTS W.
DUIVERMAN M.	MATHIOUDAKIS A.	Z
EGENDAGLID	MCCARTHY C.	ZANNIN E.
ESENDAGLI D.	MEINEDC C	
FARRELL	MELONI F.	
FABBRI L.	METERAN H.	
FALLY M.	MIGLIORE M.	
FILIPPIDIS F.	MÖLLER A.	
FISSER C.	MOOKHERJEE N.	
FROIDURE A.	MUNAVVAR M.	
FUMAGALLI G.	N	
GARRA M	NOSSENT E.	
GAPPA M.	NVDED C. A	

NYBERG A.

GEHRING U.
GIANNAKOULAS G.

62 26.03.2025

DISCUSSANT INDEX

Name, Session number

С
COTTIN V.
CRIMI C.
D
DELCROIX M.
G
GAILLARD E.
K
KOVACS G.
M
MURPHY P.
0
OLLAND A.
R
RAHMAN N.
RIVERA ORTEGA P.
U
USMANI O.
W
WILKINSON T.
Y
YORGANCIOĞLU A.
Z

ZACHARASIEWICZ A.

26.03.2025

63

SPEAKER INDEX

FRANCZUK M.

Name, Presentation number

A
AARON S.
ADAMO M.
ADDALA D.
ADEGUNSOYE A.
ADHIKARI T.
AHMED S.
AKGÜN M.
ALEJANDRE
ALCÁZAR M.
ALIBERTI S.
AMIN R.
ANDERSEN T.
ANDERSEN Z.
ANNEMA J.
ANNESI MAESANO I.
ANTONIOU K.
ASCIAK R.
ASLAM B.
В
BAFADHEL M.
BAJWAH S.
BANKA R.
BEAUCHAMP M.
BEDAWI E.
BEECH A.
BENDIXEN M.
BENDSTRUP E.
BERTOLETTI L.
BHATNAGAR R.
BINAGWAHO A.
BIZYMI N.
BLASINSKA K.
BLUM T.
BLYTH K.
BONINI M.
BONSIGNORE M.
BONTA P.
BOS L.
BOSSIOS A.
BOUCLY A.
BOURDIN A.
BOUTOU A.
BRÄUNLICH J.
BREWER N.
BREYER-KOHANSAL
R.
BROCK J.
BRUNELLI A.
BRUSSE-KEIZER M.
BRUSSELLE G.
BUGALHO DE
ALMEIDA A.
C
CABRERA LOPEZ C.
CALFEE C.
CAO Z.
CAPUA I.
CARDOSO J.
CARLSTEN C.
CASTRO J.
CASTRO J. CASTRO-RODRIGUEZ

RINDEX	
number	
<u>J.</u>	FRANKLIN R.
CAVALCANTI A.	FRANSSEN F.
CHALMERS J. CHAMBERS R.	G
CHAN A.	GAILLARD E.
CHARALAMPOPOULO	GALETTI I.
<u>S A.</u>	GAPPA M.
CHATZI V.	GARCÍA MOYANO M. GARCÍA-VIDAL C.
CHENG G.	GEHRING U.
CHEW W.	GILLE T.
CHOROSTOWSKA- WYNIMKO J.	GLASGOW A.
CHUANG H.	GLASPOLE I.
CILLONIZ CAMPOS C.	GOMPELMANN D.
CLEMM H.	GONZALEZ J.
COHEN S.	GOPALAN D.
ÇOLAK Y.	GRAY D.
CONDLIFFE R.	GROTE L.
CORDEIRO LOPES C.	GUEDES BALDI B.
CORTOT A.	GUERY J. GUGLIELMETTI L.
COTTIN V.	
COX R.	GULER S. GUPTA N.
CRIMI C.	TT
CRINER G. CROMBAG L.	HABIB G.
CRUZ J.	HADCHOUEL-
CUEVAS OCAÑA S.	DUVERGÉ A.
CURROW D.	HALLIFAX R.
CYSNEIROS A.	HAMUTCU ERSU R.
D	HAN M.
DANDANELL JUUL A.	HÄNISCH B.
DANIELS J.	HARDAVELLA G.
DE CASTRO PEREIRA	HARRISON S.
C.	HARTLEY M. HASSAN M.
DE JONGH F. DE OLIVEIRA PITTA F.	HEIJINK H.
DE SOOMER K.	HEINZER R.
DE WEVER W.	HERTH F.
DELACOURT C.	HETZEL J.
DELCROIX M.	HEUVELMANS M.
DEMEYER H.	HOEPER M.
DENNISTON P.	HOLM A.
DEQUIN P.	HOWLETT P.
DEVEREUX G.	HULL J.
DHAR R.	HUMBERT M.
DIAMANT MD Z.	HWEE L.
DORFMÜLLER P.	IODAL D
DUARTE R.	IQBAL B.
DUIVERMAN M.	ISRAEL E. J
EFFING TUDHOF T	JANKOVIC MAKEK M.
EFFING-TIJDHOF T. ESENDAGLI D.	JANSSENS L.
EVANS R.	JARA-PALOMARES L.
EVERAERTS S.	JEEBHAY M.
F	JELITTO M.
FABBRI L.	JENY F.
FALSTER C.	JIMÉNEZ CASTRO D.
FARVER-	JIWNANI S. JOHANNESSEN A.
VESTERGAARD I.	JOHANNESSEN A.
FERREIRA D.	JOHNSTON F.
FISSER C.	<u>K</u>
FOXMAN E. FRANCZUK M.	
I IN II TOLIUIX IVI.	KALKANIS A

KARAGIANNIDIS C.
KERPEL-FRONIUS A.
KHEDOE P.
КНОО Е.
KIELY D.
KIM C.
KING G.
KIVASTIK J.
KOEGELENBERG C.
KOLB M.
KONDOH Y.
KONTOGIANNI K.
KOUMBOURLIS A.
KOURANOS V.
KOVACS G. KOZIAR VASAKOVA
M.
KRAMER-GOLINKOFF E .
KREUTER M.
KUEHNI C.
KWAK N.
L
LARSON H.
LATIMER L.
LAURSEN C.
LAVENEZIANA P.
LAWN J. LEASE E.
LEASE E. LEHMANN M.
LENFERINK A.
LEROUX P.
LEWTHWAITE H.
LICHTBLAU M.
LIPMAN M.
LOEBINGER M.
LOMBARDI C.
LOUKIDES S.
LUO Z.
LYNCH G.
MACHADO E
MACHADO F. MAHÉ I.
MAHE I. MAHMOOD K.
MAITLAND-VAN DER
ZEE A. MAKONGA-
BRAAKSMA J. MALPASS A.
MANALI E.
MANGIAPAN G.
MARGARITOPOULOS G.
MARILLIER M.
MARTÍNEZ VÁZQUEZ M.
MARTIN-LOECHES I.
MARTONE F.
MASEKELA R.
MASKELL N.
MATHIOUDAKIS A.
MAURICI DA SILVA R

MAYER L

64

KALKANIS A

MCDONALDA
MCDONALD V.
MCGOWAN A.
MEIJBOOM L. MELONI F.
METERAN H.
MEYER SAUTEUR P.
MEYS R.
MIGLIORI G.
MOCUMBI A.
MÖLLER A. MONGODI S.
MONTERO ARIAS M.
MOOR C.
MOORE V.
MUKHERJEE M.
MUNSHI L.
MURPHY P.
NAFEES A.
NAVA S.
NAVALESI P.
NEDER J.
NEWCOMB D.
NIKOLIC M.
NINO G.
NORIEGA AGUIRRE L. NOSSENT E.
NOVOA N.
NYBERG A.
0
OLIVIER K.
OLIVIER K. OLLAND A.
OLIVIER K. OLLAND A. OLSSON K.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C. PRASSE A.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C. PRASSE A. PREMUDA C.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C. PRASSE A. PREMUDA C. PRÉVOST B.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C. PRASSE A. PREMUDA C. PRÉVOST B. PRIETO CAMPO Á.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C. PRASSE A. PREMUDA C. PRÉVOST B. PRISON K.
OLIVIER K. OLLAND A. OLSSON K. ONORATI P. OWENS C. P PALANGE P. PAPADOPOULOS N. PARK D. PATAKA A. PATTERSON C. PÉPIN J. PEREIRA CATARATA M. PERGER E. PICCARI L. PIETERSEN P. PIJNENBURG M. PINELLI V. PINNOCK H. PIQUILLOUD L. POLETTI V. POLVERINO E. PORSBJERG C. PRASSE A. PREMUDA C. PRÉVOST B. PRIETO CAMPO Á. PROSCH H.

RADONIC T.
RAHMAN N.
RALI P.
RANDERATH W.
REDOLFI S.
RHEE C. RIHA R.
RIVERA ORTEGA P.
RIVERA-LEBRON B.
ROCA GAS O.
RØMHILD DAVIDSEN J.
ROSENBLATT J.
ROSENKRANZ S.
ROSSITER H.
ROUX A.
ROZMAN A.
RUTTER M.
RUWISCH J.
SAGLANI S.
SAHAY S. SALIM H.
SANCHEZ O.
SANCHEZ DE LA
TORRE M.
SATIA I.
SCHAEFFER M.
SCHEIBYE-KNUDSEN M.
SCHILLER H.
SCHIZA S.
SCHLEICH F.
SCHNEEBERGER T.
SCHRAMM D.
SCHWARZ E. SCHWERK N.
SCOTTON C.
SEBERT S.
SEHGAL S.
SHAH P.
SHARMA A.
SHATTOCK A.
SHIGEMURA N.
SHLOBIN O.
SICILIANO M.
SILVA MAIA I.
SIN D.
SINGH D.
SKAARUP S.
SLEBOS D.
SMALLWOOD N.
SMITH J.
SORIANO J.
STOLZ D.
STRINGER W.
SUNDARALINGAM A.
SVANES C.
SVENNINGSSON A.
SWAMINATHAN S.
SWIFT A.

SYLVESTER K. ZOU D.

T ZURBA L.

TÁRNOKI Á TEN BRINKE A TESTELMANS D. THÉBAUD B. THOMAS M. TOMASSETTI S. TRAVERSI L. TREVOR D. TRISTAN C. TROMEUR C. TROY L. TRUDZINSKI F. TSIKRIKA S. TSIM S. TZOUVELEKIS A. ULLER L. USMANI O. UZUNHAN Y. VALENTE PINTO M. VALENZUELA C. VAN BOVEN J. VAN DE VEERDONK M. VAN DEN AARDWEG VAN DEN BERGE M. VAN DER HEIJDEN E. VAN GEFFEN W. VAN WISSEN M. VEGA M. VELTKAMP M. VERBRAECKEN J. VERHULST S. VIJVERBERG S. VIRCHOW J. VISCUSO M. VOGIATZIS I. VOLLSETER M. VOLPATO E. VOLPI S. VOLPICELLI G. VRIJHEID M. WALKER S. WALTER K. WAPENAAR - DE KORVER M. WATZ H. WAUTERS J. WEATHERALD J. WIJSENBEEK M. WILKINSON T. YILDIRIM A. YORGANCIOĞLU A.

ZACHARASIEWICZ A.

ZAR H.

26.03.2025

65

AUTHOR INDEX Name, Abstract number